<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and management of suspected sepsis and septic shock in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and management of suspected sepsis and septic shock in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation and management of suspected sepsis and septic shock in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory A Schmidt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jess Mandel, MD, MACP, ATSF, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel J Sexton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Korilyn S Zachrison, MD, MSc</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Ng Gong, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 09, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Sepsis is a clinical syndrome characterized by systemic inflammation due to infection. There is a continuum of severity ranging from sepsis to septic shock. Although wide-ranging and dependent upon the population studied, mortality has been estimated to be ≥10 percent and ≥40 percent when shock is present [<a href="#rid1">1,2</a>].</p><p>In this topic review, the management of sepsis and septic shock is discussed. Our approach is consistent for the most-part with 2021 guidelines issued by the Surviving Sepsis Campaign [<a href="#rid3">3,4</a>].</p><p>While we use the Society of Critical Care Medicine (SCCM)/European Society of Intensive Care Medicine (ESICM) definitions, such definitions are not unanimously accepted. For example, the Center for Medicare and Medicaid Services (CMS) still continues to support the previous definition of systemic inflammatory response syndrome, sepsis, and severe sepsis. In addition, the Infectious Diseases Society of America (IDSA) has pointed out that use of such definitions, while lifesaving for those with shock, may lead to overtreatment with broad-spectrum antibiotics for those with milder variants of sepsis [<a href="#rid5">5</a>].</p><p>Definitions, diagnosis, pathophysiology, and investigational therapies for sepsis, as well as management of sepsis in the asplenic patient are reviewed separately. (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis"</a> and  <a class="medical medical_review" href="/d/html/1597.html" rel="external">"Pathophysiology of sepsis"</a> and  <a class="medical medical_review" href="/d/html/1631.html" rel="external">"Investigational and ineffective pharmacologic therapies for sepsis"</a> and  <a class="medical medical_review" href="/d/html/1404.html" rel="external">"Clinical features, evaluation, and management of fever in patients with impaired splenic function"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">IMMEDIATE EVALUATION AND MANAGEMENT</span><span class="headingEndMark"> — </span>Securing the airway (if indicated) and correcting hypoxemia, and establishing venous access for the <strong>early</strong> administration of fluids and antibiotics are priorities in the management of patients with sepsis and septic shock [<a href="#rid3">3,4</a>]. The following table summarizes emergency management of the patient with severe sepsis during the first hour  (<a class="graphic graphic_table graphicRef143200" href="/d/graphic/143200.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H4"><span class="h2">Stabilize respiration</span><span class="headingEndMark"> — </span>Supplemental oxygen should be supplied to all patients with sepsis who have indications for oxygenation, and oxygenation should be monitored continuously with pulse oximetry. Ideal target values for peripheral saturation are unknown, but we typically target values between 90 and 96 percent. Intubation and mechanical ventilation may be required to support the increased work of breathing that frequently accompanies sepsis or for airway protection since encephalopathy and a depressed level of consciousness frequently complicate sepsis [<a href="#rid6">6,7</a>]. Target values for oxygenation, techniques and sedative and induction agents for intubation are discussed separately. (See  <a class="medical medical_review" href="/d/html/1640.html" rel="external">"Overview of initiating invasive mechanical ventilation in adults in the intensive care unit", section on 'Fraction of inspired oxygen'</a> and  <a class="medical medical_review" href="/d/html/271.html" rel="external">"Induction agents for rapid sequence intubation in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/d/html/276.html" rel="external">"Overview of advanced airway management in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/d/html/270.html" rel="external">"Rapid sequence intubation in adults for emergency medicine and critical care"</a> and  <a class="medical medical_review" href="/d/html/268.html" rel="external">"The decision to intubate"</a> and  <a class="medical medical_review" href="/d/html/260.html" rel="external">"Direct laryngoscopy and endotracheal intubation in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Establish venous access</span><span class="headingEndMark"> — </span>Venous access should be established as soon as possible in patients with suspected sepsis. While peripheral venous or intraosseous access may be sufficient in some patients, particularly for initial resuscitation, the majority will require central venous access at some point during their course. However, the insertion of a central line should not delay the administration of resuscitative fluids and antibiotics. A central venous catheter (CVC) can be used to infuse intravenous fluids, medications (particularly vasopressors), and blood products, as well as to draw blood for frequent laboratory studies. While a CVC can be used to monitor the therapeutic response by measuring the central venous pressure (CVP) and the central venous oxyhemoglobin saturation (ScvO<sub>2</sub>), evidence from randomized trials suggest that their value is limited [<a href="#rid8">8-13</a>]. (See  <a class="medical medical_review" href="/d/html/8180.html" rel="external">"Central venous catheters: Overview of complications and prevention in adults"</a> and <a class="local">'Monitor response'</a> below.)</p><p class="headingAnchor" id="H368566500"><span class="h2">Initial investigations</span><span class="headingEndMark"> — </span>An initial brief history and examination, as well as laboratory, microbiologic (including blood cultures), and imaging studies are often obtained simultaneously while access is being established and the airway stabilized. This brief assessment yields clues to the suspected source and complications of sepsis, and therefore, helps guide empiric therapy and additional testing  (<a class="graphic graphic_table graphicRef59769" href="/d/graphic/59769.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Clinical presentation'</a> and <a class="local">'Empiric antibiotic therapy (first hour)'</a> below.)</p><p>Quickly obtaining the following is preferable (within 45 minutes of presentation) but should not delay the administration of fluids and antibiotics:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood counts with differential, chemistries, liver function tests, and coagulation studies including D-dimer level. Results from these studies may support the diagnosis, indicate the severity of sepsis, and provide baseline to follow the therapeutic response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum lactate – An elevated serum lactate (eg, &gt;2 mmol/L or greater than the laboratory upper limit of normal) may indicate the severity of sepsis and is used to follow the therapeutic response [<a href="#rid3">3,4,14-16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood cultures (aerobic and anaerobic cultures from at least two different sites), urinalysis, and microbiologic cultures from suspected sources (eg, sputum, urine, intravascular catheter, wound or surgical site, body fluids, rapid antigen or polymerase chain reaction tests) from readily accessible sites. Drawing blood for cultures through an indwelling or central intravascular catheter should be avoided whenever possible since ports are frequently colonized with skin flora, thereby increasing the likelihood of a false-positive blood culture. If blood cultures are drawn from an intravenous line, a second specimen should be drawn from a peripheral venipuncture site.</p><p></p><p class="bulletIndent1">The importance of early blood cultures was best illustrated in a multicenter randomized trial of 325 patients with a presumed or confirmed source of infection and hypotension or elevated lactate &gt;4 mmol/L [<a href="#rid17">17</a>]. All patients had two sets of blood cultures drawn from two separate sites before antimicrobial administration and a second set of blood cultures was obtained from zero to four hours after antimicrobial administration. Pre-antimicrobial cultures were positive in 31.4 percent compared with 19.4 percent post-antimicrobial administration. When pre-antimicrobial cultures were considered the reference gold standard, the sensitivity of post-antimicrobial blood cultures was 53 percent. When other cultures were included with post-antimicrobial blood cultures, pathogens were identified in approximately two-thirds of patients. Although some methodologic issues (eg, in some patients only one blood culture or one venipuncture was obtained instead of two), this study nonetheless highlights the importance of taking blood cultures prior to antimicrobial administration. Importantly, both the collection of cultures and the initiation of antimicrobial therapy should be prompt in those with the signs of severe sepsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Arterial blood gas (ABG) analysis – ABGs may reveal acidosis, hypoxemia, or hypercapnia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Imaging targeted at the suspected site of infection is warranted (eg, chest radiography, computed tomography of chest and/or abdomen).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procalcitonin – While the diagnostic value of procalcitonin in patients with sepsis is poorly supported by evidence, its value in de-escalating antibiotic therapy is well established in populations, in particular, those with community acquired pneumonia and respiratory tract infections; measurement of procalcitonin to guide duration of antibiotic use is appropriate in those populations with sepsis, while its role in other groups is unclear. While one meta-analysis of 5158 critically ill patients reported a mortality benefit associated with procalcitonin use a survival benefit was not noted in the subset of patients with sepsis [<a href="#rid18">18</a>]. In contrast, a randomized trial of 266 patients with sepsis from lower respiratory tract infections, acute pyelonephritis, or primary bloodstream infection, procalcitonin guided therapy was associated with a reduction in 28-day mortality (28 versus 15 percent) and length of antibiotic therapy (5 versus 10 days) [<a href="#rid19">19</a>]. While encouraging, additional data from well-conducted randomized trials in patients with sepsis are required before we can routinely recommend procalcitonin use all patients with sepsis. Detailed evidence to support the use of procalcitonin is provided separately. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections"</a> and  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Serum biomarkers'</a>.)</p><p></p><p class="headingAnchor" id="H3877618"><span class="h1">INITIAL RESUSCITATIVE THERAPY</span><span class="headingEndMark"> — </span>The cornerstone of initial resuscitation is the rapid restoration of perfusion and the early administration of antibiotics. The following table summarizes emergency management of the patient with severe sepsis during the first hour  (<a class="graphic graphic_table graphicRef143200" href="/d/graphic/143200.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Tissue perfusion is predominantly achieved by the aggressive administration of intravenous fluids (IVF), usually crystalloids (balanced crystalloids or normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) given at 30 mL/kg (actual body weight), started by one hour and completed within the first <strong>three</strong> hours following presentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Empiric antibiotic therapy is targeted at the suspected organism(s) and site(s) of infection and preferably administered within the <strong>first</strong> hour.</p><p></p><p>Our approach is based upon several major randomized trials that used a protocol-based approach (ie, early goal-directed therapy [EGDT]) to treating sepsis [<a href="#rid8">8-13</a>]. Components of the protocols usually included the early administration of fluids and antibiotics (within one to six hours) using the following targets to measure the response: central venous oxyhemoglobin saturation (ScvO<sub>2</sub>) ≥70 percent, central venous pressure (CVP) 8 to 12 mmHg, mean arterial pressure (MAP) ≥65 mmHg, and urine output ≥0.5 mL/kg/hour. Although all trials [<a href="#rid9">9-11</a>] (except for one [<a href="#rid8">8</a>]) did not show a mortality benefit to EGDT, it is thought that the lack of benefit was explained by an overall improved outcome in both control and treatment groups and to improved clinical performance by trained clinicians in academic centers during an era that followed an aggressive sepsis education and management campaign. In support of this hypothesis is that central line placement was common (&gt;50 percent) in control groups so it is likely that CVP, ScvO<sub>2</sub>, and/or lactate clearance were targeted in these patients. Furthermore, the mortality in studies that did not report a benefit to EGDT [<a href="#rid9">9-11</a>] approximated that of the treatment arm in the only study that reported benefit [<a href="#rid8">8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>One single center randomized trial of 263 patients with suspected sepsis reported a lower mortality in patients when ScvO<sub>2</sub>, CVP, MAP, and urine output were used to direct therapy compared with those in whom only CVP, MAP, and urine output were targeted (31 versus 47 percent) [<a href="#rid8">8</a>]. Both groups initiated therapy, including antibiotics, within six hours of presentation. There was a heavy emphasis on the use of red cell transfusion (for a hematocrit &gt;30) and <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> to reach the ScvO<sub>2</sub> target in this trial.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three subsequent multicenter randomized trials of patients with septic shock, ProCESS [<a href="#rid9">9</a>], ARISE [<a href="#rid10">10</a>], and ProMISE [<a href="#rid11">11</a>] and two meta-analyses [<a href="#rid12">12,13</a>] all reported no mortality benefit (mortality ranged from 20 to 30 percent), associated with an identical protocol compared with protocols that used some of these targets or usual care. In contrast, one meta-analysis of 13 trials reported a mortality benefit from early-goal directed therapy within the first six hours [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A lack of benefit of resuscitation protocols has also been reported in resource-limited settings. As an example, in a randomized trial of 212 patients with sepsis (defined as suspected infection plus two systemic inflammatory response syndrome criteria) and hypotension (systolic blood pressure ≤90 mmHg or MAP &lt;65 mmHg) in Zambia, a protocolized approach of aggressive fluid resuscitation, monitoring, blood, and vasopressor transfusion within the first six hours of presentation resulted in a higher rate of death (48 versus 33 percent) when compared with usual care [<a href="#rid21">21</a>]. However, several flaws including crude measurements of monitoring, lower than usual rates of lactate elevation, larger than typical volumes of fluid resuscitation, and use of <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> (as opposed to <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a>) in a population with a high percentage of patients with human immunodeficiency virus may have biased the results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another analysis from a cohort of 1871 Canadian patients reported that prehospital administration of fluids by paramedics to patients with hypotension from sepsis may be of benefit, although it was associated with increased prehospital time [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A post-hoc analysis of the ANROMEDA-SHOCK trial [<a href="#rid23">23</a>] suggested that peripheral perfusion-targeted resuscitation (using capillary refill time [CRT]) may be associated with a lower mortality and faster resolution of organ dysfunction than lactate-targeted resuscitation [<a href="#rid24">24</a>]. Additional studies suggest a poor correlation between MAP and CRT [<a href="#rid25">25</a>]. Further study is required before clinicians should use CRT routinely as a marker of resuscitation.</p><p></p><p>The importance of timely treatment, particularly with antibiotics, was illustrated in a database study of nearly 50,000 patients with sepsis and septic shock who were treated with various types of protocolized treatment bundles (that included fluids and antibiotics, blood cultures, and serum lactate measurements) [<a href="#rid26">26</a>]. Compared with those in whom a three-hour bundle (blood cultures before broad spectrum antibiotics, serum lactate level) was completed within the three-hour time frame, a higher in-hospital mortality was reported when a three-hour bundle was completed later than three hours (odds ratio [OR] 1.04 per hour). Increased mortality was associated with the delayed administration of antibiotics but not with a longer time to completion of a fluid bolus (as part of a six hour bundle) (OR 1.04 per hour versus 1.10 per hour).</p><p class="headingAnchor" id="H10"><span class="h2">Intravenous fluids (first three hours)</span><span class="headingEndMark"> — </span>In patients with sepsis, intravascular hypovolemia is typical and may be severe, requiring rapid fluid resuscitation. (See  <a class="medical medical_review" href="/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults"</a>.)</p><p class="headingAnchor" id="H465649886"><span class="h3">Volume</span><span class="headingEndMark"> — </span>Intravascular hypovolemia is typical and may be severe in sepsis. Rapid, large volume infusions of IVF (30 mL/kg) are indicated as initial therapy for severe sepsis or septic shock, unless there is convincing evidence of significant pulmonary edema. This approach is based upon several randomized trials that reported no difference in mortality when mean infusion volumes of 2 to 3 liters were administered in the first three hours [<a href="#rid9">9-11</a>] compared with larger volumes of three to five liters, which was considered standard therapy at the time [<a href="#rid8">8</a>]. However, some patients may require higher than recommended volumes, particularly those who demonstrate clinical and/or hemodynamic indicators of fluid-responsiveness. (See <a class="local">'Monitor response'</a> below.)</p><p>Fluid therapy should be administered in well-defined (eg, 500 mL), rapidly infused boluses. The clinical and hemodynamic response and the presence or absence of pulmonary edema must be assessed before and after each bolus. Intravenous fluid challenges can be repeated until blood pressure and tissue perfusion are acceptable, pulmonary edema ensues, or fluid fails to augment perfusion.</p><p>In one trial, over 1500 patients with sepsis-induced hypotension refractory to initial resuscitation with 1 to 3 L of IVF were randomized to receive either a restrictive fluid regimen (prioritizing vasopressors and lower intravenous fluid volumes) or liberal fluid regimen (prioritizing higher volumes of intravenous fluids before vasopressor use). The restrictive strategy entailed early administration of vasopressors after infusion of up to 2 L of fluid including prerandomization fluid, if needed. The liberal regimen prioritized infusion of an additional 2 L at randomization in addition to prerandomized fluid and additional boluses as needed [<a href="#rid27">27</a>]. Despite more fluid administration in the liberal group compared with the restrictive group (3400 versus 1267mL at 24 hours), there was no difference in 90-day mortality (15 versus 14 percent) or any other outcome measured. Vasopressors were administered earlier and for longer periods in those who received the restrictive regimen but did not appear to be associated with excess adverse effects. However, results may have been impacted by greater than intended fluid volumes administered in some patients in the restrictive group and lower than intended volumes in some patients in the liberal group, perhaps limiting the ability of the study to detect a meaningful difference between the interventions. In addition, the median volume administered in the liberal group is reasonably close to that which is widely practiced and both arms of this trial led to administration of significantly less fluid than would have been typical a decade ago; this suggests that adopting a more aggressive restrictive approach than currently practiced may not be associated with additional benefit.</p><p class="headingAnchor" id="H465649907"><span class="h3">Choice of fluid</span><span class="headingEndMark"> — </span>Evidence from randomized trials and meta-analyses have found no convincing difference between using albumin solutions and crystalloid solutions (eg, Ringer's lactate, normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>) in the treatment of sepsis or septic shock, but they have identified potential harm from using <a class="drug drug_general" data-topicid="10203" href="/d/drug information/10203.html" rel="external">pentastarch</a> or hydroxyethyl starch [<a href="#rid28">28-37</a>]. There is no role for hypertonic saline [<a href="#rid38">38</a>].</p><p>In our practice, we generally use a balanced crystalloid solution, and less commonly, normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>, instead of an <a class="drug drug_general" data-topicid="9376" href="/d/drug information/9376.html" rel="external">albumin solution</a> because of the lack of clear benefit and higher cost of albumin. Balanced crystalloid rather than normal saline is preferred if there is a perceived need to avoid or treat the hyperchloremia that occurs when large volumes of nonbuffered crystalloid (eg, normal saline) are administered, although the data to support this practice are weak (and discussed separately). (See  <a class="medical medical_review" href="/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Choice of replacement fluid'</a>.)</p><p>Data discussing IVF choice among patients with sepsis include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crystalloid versus albumin</strong> – Among patients with sepsis, several randomized trials and meta-analyses have reported no difference in mortality when albumin was compared with crystalloids, although one meta-analysis suggested benefit in those with septic shock [<a href="#rid29">29,36,37</a>]. In the <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">Saline</a> versus Albumin Fluid Evaluation (SAFE) trial performed in critically ill patients, there was no benefit to albumin compared with saline even in the subgroup with severe sepsis, who comprised 18 percent of the total group [<a href="#rid28">28</a>]. Among the crystalloids, there are no guidelines to suggest that one form is more beneficial than the other.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crystalloid versus hydroxyethyl starch (HES)</strong> – In the Scandinavian Starch for Severe Sepsis and Septic Shock (6S) trial, compared with Ringer's acetate, use of HES resulted in increased mortality (51 versus 43 percent) and renal replacement therapy (22 versus 16 percent) [<a href="#rid30">30</a>]. Similar results were found in additional trials of patients without sepsis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crystalloid versus </strong><a class="drug drug_general" data-topicid="10203" href="/d/drug information/10203.html" rel="external">pentastarch</a> – The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) trial compared pentastarch to modified Ringer's lactate in patients with severe sepsis and found no difference in 28-day mortality [<a href="#rid31">31</a>]. The trial was stopped early because there was a trend toward increased 90-day mortality among patients who received pentastarch.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Balanced salt solutions</strong> – Evidence to support the use of a balanced crystalloid solution or 0.9 percent <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> in patients with sepsis is indirect and mostly derived from studies performed in a mixed population of critically ill patients. Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Choosing between 0.9 percent saline and buffered crystalloid'</a>.)</p><p></p><p class="headingAnchor" id="H4239562462"><span class="h3">Treating metabolic acidosis</span><span class="headingEndMark"> — </span>Whether metabolic acidosis associated with sepsis should be treated with bicarbonate is discussed separately. (See  <a class="medical medical_review" href="/d/html/2294.html" rel="external">"Bicarbonate therapy in lactic acidosis"</a>.)</p><p class="headingAnchor" id="H1633281939"><span class="h2">Empiric antibiotic therapy (first hour)</span><span class="headingEndMark"> — </span>Prompt identification and treatment of the site(s) of infection is the primary therapeutic intervention, with most other interventions being purely supportive.</p><p class="headingAnchor" id="H2563203496"><span class="h3">Identification of suspected source</span><span class="headingEndMark"> — </span>Empiric antibiotics should be targeted at the suspected source(s) of infection which is typically identified from the initial history, physical examination, and preliminary laboratory findings and imaging  (<a class="graphic graphic_table graphicRef59769" href="/d/graphic/59769.html" rel="external">table 2</a>) (see <a class="local">'Initial investigations'</a> above). However, additional diagnostic testing or interventions may be required to identify the anatomic site(s) of infection. In particular, in addition to antibiotics, closed-space infections should be promptly drained or debrided (eg, empyema, abscess) for effective source control. (See <a class="local">'Septic focus identification and source control'</a> below.)</p><p class="headingAnchor" id="H3417960630"><span class="h3">Timing</span><span class="headingEndMark"> — </span>Once a presumed diagnosis of sepsis or septic shock has been made, optimal doses of appropriate intravenous antibiotic therapy should be initiated, preferably within one hour of presentation and after cultures have been obtained (see <a class="local">'Initial investigations'</a> above). The early administration of antimicrobials is often challenging because various patient- and institutional-related factors may lead to delays in timely treatment [<a href="#rid39">39</a>]. Institutional protocols should address timeliness as a quality improvement measure [<a href="#rid40">40</a>]. However, several clinician groups including the Infectious Diseases Society of America (IDSA) criticized the Society of Critical Care Medicine (SCCM) for promoting standards defining rigid time frames for initiation of antibiotics as it is often difficult to determine the actual onset of sepsis in individual patients; in addition, the one hour time frame could lead to overuse and inappropriate administration of unwarranted antimicrobials [<a href="#rid5">5,41</a>]. The IDSA favors removal of a recommendation for specific minimum time frames for initiating antibiotic therapy and instead advocates replacing these recommendations with the statement that prompt administration of antibiotics is recommended once a presumed diagnosis of sepsis or shock has been made by the treating clinician [<a href="#rid5">5</a>].</p><p>Although the feasibility of a one hour target for initiating antibiotics has not been assessed, the rationale for choosing it is based upon observational studies that report poor outcomes with delayed (even beyond one hour), inadequately dosed, or inappropriate (ie, treatment with antibiotics to which the pathogen was later shown to be resistant in vitro) antimicrobial therapy [<a href="#rid42">42-52</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective analysis of over 17,000 patient with sepsis and septic shock, delay in first antibiotic administration was associated with increased in-hospital mortality with a linear increase in the risk of mortality for each hour delay in antibiotic administration [<a href="#rid50">50</a>]. Similar results were reported in an emergency department cohort of 35,000 patients [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prospective cohort study of 2124 patients demonstrated that inappropriate antibiotic selection was surprisingly common (32 percent) [<a href="#rid46">46</a>]. Mortality was markedly increased in these patients compared with those who had received appropriate antibiotics (34 versus 18 percent).</p><p></p><p class="headingAnchor" id="H2634735011"><span class="h3">Choosing a regimen</span><span class="headingEndMark"> — </span>The choice of antimicrobials can be complex and should consider the patient's history (eg, recent antibiotics received, previous organisms), comorbidities (eg, diabetes, organ failures), immune defects (eg, human immune deficiency virus), clinical context (eg, community- or hospital-acquired), suspected site of infection, presence of invasive devices, Gram stain data, and local prevalence and resistance patterns [<a href="#rid53">53-57</a>]. The general principles and examples of potential empiric regimens are given in this section but antimicrobial choice should be <strong>tailored to each individual</strong>.</p><p>For most patients with sepsis without shock, we recommend empiric broad spectrum therapy with one or more antimicrobials to cover all likely pathogens. Coverage should be directed against both gram-positive and gram-negative bacteria and, if indicated, against fungi (eg, <em>Candida</em>) and occasionally viruses (eg, influenza, coronavirus disease 2019 [COVID-19]). Broad spectrum is defined as therapeutic agent(s) with sufficient activity to cover a range of gram-negative and gram-positive organisms (eg, carbapenem, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>). In order to ensure treatment with an effective antibiotic, many patients with septic shock suspected to be due to gram-negative organisms may require initial therapy with two antimicrobials from two different classes (ie, combination therapy), although this practice depends upon the organisms that are considered likely pathogens and local antibiotic susceptibilities.</p><p>Empiric therapy for patients with sepsis should be directed at the most common organisms causing sepsis in specific patient populations. Among organisms isolated from patients with sepsis, the most common include <em>Escherichia coli</em>, <em>Staphylococcus aureus</em>, <em>Klebsiella pneumoniae</em>, and <em>Streptococcus pneumoniae</em>, such that coverage of these organisms should be kept in mind when choosing an agent [<a href="#rid58">58</a>].</p><p>However, when the organism is unknown, the clinician should be mindful of other potential pathogens when risk factors are present and consider the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Methicillin-resistant <em>S. aureus</em> – Methicillin-resistant <em>S. aureus</em> (MRSA) is a cause of sepsis not only in hospitalized patients but also in community dwelling individuals without recent hospitalization [<a href="#rid59">59,60</a>]. For these reasons, we suggest empiric intravenous <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (adjusted for renal function) be added to empiric regimens, particularly in those with shock or those at risk for MRSA. Potential alternative agents to vancomycin (eg, <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> for nonpulmonary MRSA, <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>) should be considered for patients with refractory or virulent MRSA or with a contraindication to vancomycin. (See  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a> and  <a class="medical medical_review" href="/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Risk factors for MRSA'</a>.)</p><p></p><p class="bulletIndent1">In our practice, if <em>Pseudomonas</em> is an unlikely pathogen, we favor combining <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> with one of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A third generation (eg, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a>) or fourth generation cephalosporin (<a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A beta-lactam/beta-lactamase inhibitor (eg, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A carbapenem (eg, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> or <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Pseudomonas</em> – Alternatively, if <em>Pseudomonas</em> is a likely pathogen, we favor combining <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> with one to two of the following, depending on local antibiotic susceptibility patterns (see  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antipseudomonal cephalosporin (eg, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antipseudomonal carbapenem (eg, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antipseudomonal beta-lactam/beta-lactamase inhibitor (eg, <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fluoroquinolone with good anti-pseudomonal activity (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aminoglycoside (eg, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>), or</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Monobactam (eg, <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>)</p><p></p><p class="bulletIndent1">Choosing among the preceding options should be individualized. <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">Cefepime</a> and <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> are probably the most commonly prescribed antipseudomonal agents. Piperacillin-tazobactam has been hypothesized to cause acute kidney injury, and cefepime has been hypothesized to cause neurologic dysfunction. Use of these two agents were directly compared in a randomized trial of 2511 patients with suspected infection who needed empiric treatment with an antipseudomonal agent [<a href="#rid61">61</a>]. Rates of acute kidney injury or death by day 14 were similar between the two groups. In contrast, patients in the cefepime group experienced fewer days alive and free of delirium and coma (11.9 versus 12.2 days; odds ratio 0.79, 95% CI 0.65-0.95), although the difference, while significant, was small. Interpretation is limited since the study was an open-label trial with significant crossover between the groups and longer-term outcomes beyond 14 days are not known. In addition, the dosing regimen was lower than typical for piperacillin-tazobactam and cefepime was administered as an intravenous push, which may have increased the risk of neurotoxicity. Lastly, the role of other antibiotics, such as anaerobic coverage with <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>, was not examined in this study. Further details regarding the adverse effects of beta-lactam antibiotics are provided elsewhere. (See  <a class="medical medical_review" href="/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Non pseudomonal gram-negative organisms (eg, <em>E. coli</em>, <em>K. pneumoniae</em>) – In the past, gram-negative pathogens routinely were covered with two agents from different antibiotic classes. However, several clinical trials and two meta-analyses failed to demonstrate superior overall efficacy of combination therapy compared to monotherapy with a third generation cephalosporin or a carbapenem [<a href="#rid46">46,62-66</a>]. Furthermore, one meta-analysis found double coverage that included an aminoglycoside was associated with an increased incidence of adverse events (nephrotoxicity) [<a href="#rid65">65,66</a>]. For this reason, in patients with suspected gram-negative pathogens, we recommend use of a single agent with proven efficacy and the least possible toxicity, except in patients who are either neutropenic or whose sepsis is due to a known or suspected <em>Pseudomonas</em> infection, where combination therapy can be considered [<a href="#rid64">64</a>]. (See  <a class="medical medical_review" href="/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a> and  <a class="medical medical_review" href="/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Invasive fungal infections – The <strong>routine</strong> administration of empirical antifungal therapy is not generally warranted in <strong>nonneutropenic</strong> critically ill patients. Invasive fungal infections occasionally complicate the course of critical illness, especially when the following risk factors are present: surgery, <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a>, prolonged antimicrobial treatment or hospitalization (especially in the intensive care unit [ICU]), chemotherapy, transplant, chronic liver or renal failure, diabetes, major abdominal surgery, vascular devices, septic shock or multisite colonization with <em>Candida</em> spp. However, studies do not support the routine use of empiric antifungals in this population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of 22 studies (most often comparing <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a> to placebo, but also using <a class="drug drug_general" data-topicid="8589" href="/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="8744" href="/d/drug information/8744.html" rel="external">anidulafungin</a>, <a class="drug drug_general" data-topicid="9175" href="/d/drug information/9175.html" rel="external">caspofungin</a>, <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a>, and amphotericin B), untargeted empiric antifungal therapy possibly reduced fungal colonization and the risk of invasive fungal infection but did not reduce all-cause mortality [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study of critically ill patients ventilated at least five days, empiric antifungal treatment (mostly <a class="drug drug_general" data-topicid="8450" href="/d/drug information/8450.html" rel="external">fluconazole</a>) was not associated with a decreased risk of mortality or occurrence of invasive candidiasis [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter randomized trial (EMPIRICUS) of 260 nonneutropenic critically ill patients with <em>Candida</em> colonization (at multiple sites), multiple organ failure, and ICU-acquired sepsis, empiric treatment for 14 days with <a class="drug drug_general" data-topicid="10141" href="/d/drug information/10141.html" rel="external">micafungin</a> did not result in improved infection-free survival at 28 days but did decrease the rate of new fungal infection [<a href="#rid69">69</a>].</p><p></p><p class="bulletIndent1">However, if <em>Candida</em> or <em>Aspergillus</em> is strongly <strong>suspected</strong> or if neutropenia is present, an echinocandin (for <em>Candida</em>) or <a class="drug drug_general" data-topicid="10118" href="/d/drug information/10118.html" rel="external">voriconazole</a> (for <em>Aspergillus</em>) are often appropriate. (See  <a class="medical medical_review" href="/d/html/2459.html" rel="external">"Treatment and prevention of invasive aspergillosis"</a> and  <a class="medical medical_review" href="/d/html/2430.html" rel="external">"Management of candidemia and invasive candidiasis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other – Other regimens should consider the inclusion of agents for specific organisms such as <em>Legionella</em> (macrolide or fluoroquinolone) or difficult to treat organisms (eg, <em>Stenotrophomonas</em>), or for specific conditions (eg, neutropenic bacteremia)</p><p></p><p class="headingAnchor" id="H4063271367"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>Clinicians should pay attention to maximizing the dose in patients with sepsis and septic shock using a full "high-end" loading dose where possible. This strategy is based upon the known increased volume of distribution that can occur in patients with sepsis due to the administration of fluid [<a href="#rid70">70-72</a>] and that higher clinical success rates have been reported in patients with higher peak concentrations of antimicrobials [<a href="#rid73">73-75</a>].</p><p>Continuous infusions of antibiotics as compared with intermittent dosing regimens remains investigational at this time [<a href="#rid76">76</a>]. Continuous infusions of beta lactam antimicrobials have been shown to provide higher and sustained drug levels above the minimum inhibitory concentration compared with the peaks and trough of intermittent dosing [<a href="#rid77">77-79</a>]. In a double-blind randomized trial of 607 patients prescribed <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> for sepsis, outcomes were compared when meropenem was administered as a continuous infusion or intermittent infusion [<a href="#rid80">80</a>]. The mode of administration did not affect the composite outcome of 28-day mortality and the emergence of pandrug-resistant bacteria (47 versus 49 percent). In addition, there also was no difference in the length of ICU or hospital stay, days alive and free from the ICU, or 90-day mortality. However, therapeutic monitoring was not performed and the prescription of other microbials was common, both of which may limit the ability to detect a difference between the groups. We believe that further study is needed before continuous infusions can be recommended, although some experts favor continuous infusions given study biases, lack of harm, and possibility of benefit. Further details on prolonged infusions of antimicrobials are provided separately. (See  <a class="medical medical_review" href="/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p class="headingAnchor" id="H2720158431"><span class="h2">Location of admission</span><span class="headingEndMark"> — </span>Whether patients should be admitted to an ICU or ward is unclear and likely varies with the individual presenting characteristics as well as available institutional services and policy, which also may vary from state to state and country to country. For example, patients with septic shock who require mechanical ventilation and vasopressors clearly require ICU admission while those without shock who quickly respond to fluid and antibiotics may be safely transferred to the floor. For those in between these extremes, close observation and a low threshold to admit to the ICU is prudent.</p><p>Use of a systematic approach to ICU admission has been studied. One study of 3037 critically ill French patients aged 75 years or older, randomized patients to hospitals that promoted a systematic approach to ICU admission (interventional group) or to hospitals that did not use this approach (usual care) [<a href="#rid81">81</a>]. Despite a doubling of the admission rate to the ICU and an increased risk of in-hospital death, there was no difference in mortality at six months after adjustment for age, illness severity, initial clinical diagnosis, seniority of the emergency department clinician, time of ICU admission, baseline functional status, living situation, and type of home support. However, several flaws including, higher severity of illness in the intervention group, lack of blinding, and a strategy that was underpowered to detect a mortality difference may have influenced these results. In addition, international differences in the care of patients with sepsis may also explain an opposing outcome reported by a United States cohort [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H2170293153"><span class="h1">MONITOR RESPONSE</span><span class="headingEndMark"> — </span>After fluids and empiric antibiotics have been administered, the therapeutic response should be assessed frequently. We suggest that clinical, hemodynamic, and laboratory parameters be followed as outlined in the sections below. In our experience, most patients respond within the first 6 to 24 hours to initial fluid therapy, however, resolution can be protracted and take days or weeks. The response mostly influences further fluid management but can also affect antimicrobial therapy and source control.</p><p class="headingAnchor" id="H3514478798"><span class="h2">Monitoring catheters</span><span class="headingEndMark"> — </span>For many patients, a central venous catheter (CVC) and an arterial catheter are placed, although they are not always necessary. For example, an arterial catheter may be inserted if blood pressure is labile, sphygmomanometer readings are unreliable, restoration of perfusion is expected to be protracted (especially when vasopressors are administered), or dynamic measures of fluid responsiveness are selected to follow the hemodynamic response. A CVC may be placed if the infusion of large volumes of fluids or vasopressors are anticipated, peripheral access is poor, or the central venous pressure (CVP) or the central venous oxyhemoglobin saturation (ScvO<sub>2</sub>) are chosen as methods of monitoring the hemodynamic response. (See  <a class="medical medical_review" href="/d/html/8174.html" rel="external">"Intra-arterial catheterization for invasive monitoring: Indications, insertion techniques, and interpretation"</a> and  <a class="medical medical_review" href="/d/html/107337.html" rel="external">"Novel tools for hemodynamic monitoring in critically ill patients with shock"</a> and  <a class="medical medical_review" href="/d/html/8194.html" rel="external">"Central venous access in adults: General principles"</a>.)</p><p>We believe that pulmonary artery catheters (PACs) should <strong>not</strong> be used in the routine management of patients with sepsis or septic shock since they have not been shown to improve outcome [<a href="#rid83">83-85</a>]. PACs can measure the pulmonary artery occlusion pressure (PAOP) and mixed venous oxyhemoglobin saturation (SvO<sub>2</sub>). However, the PAOP has proven to be a poor predictor of fluid responsiveness in sepsis and the SvO<sub>2</sub> is similar to the ScvO<sub>2</sub>, which can be obtained from a CVC [<a href="#rid86">86,87</a>]. (See  <a class="medical medical_review" href="/d/html/1593.html" rel="external">"Pulmonary artery catheterization: Indications, contraindications, and complications in adults"</a>.)</p><p class="headingAnchor" id="H1643153952"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>All patients should be followed clinically for improved mean arterial pressure (MAP), urine output, heart rate, respiratory rate, skin color, temperature, pulse oximetry, and mental status. Among these, a MAP ≥65 mmHg (MAP = [(2 x diastolic) + systolic]/3) (<a class="calc calc_professional" href="/d/html/101851.html" rel="external">calculator 1</a>), and urine output ≥0.5 mL/kg per hour are common targets used in clinical practice. They have not been compared to each other nor have they been proven to be superior to any other target or to clinical assessment. Data supporting the use of these clinical parameters are discussed above. (See <a class="local">'Initial resuscitative therapy'</a> above.)</p><p>Most clinicians target a MAP ≥65 mmHg based upon data from large randomized trials that demonstrated benefit when using this target MAP (see <a class="local">'Initial resuscitative therapy'</a> above). However, the ideal target for MAP, is unknown. Furthermore, data since then suggest that higher MAPs (eg, ≥70 mmHg) may be harmful, while targeting lower MAPs (eg, 60 to 65 mmHg) may be appropriate. Thus, a reasonable goal may be to individualize targets within a range (eg, 60 to 70 mmHg) rather than targeting one specific numeric goal. Further trials are pending that should help elucidate an optimal range for a target MAP for patients with hypotension from sepsis.</p><p class="bulletIndent1"><span class="glyph">●</span>One trial that randomized patients to a target MAP of 65 to 70 mmHg (low target MAP) or 80 to 85 mmHg (high target MAP) reported no mortality benefit to targeting a higher MAP [<a href="#rid88">88</a>]. Patients with a higher MAP had a greater incidence of atrial fibrillation (7 versus 3 percent), suggesting that targeting a MAP &gt;80 mmHg is potentially harmful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A pilot randomized trial reported that among patients aged 75 years or older, a higher MAP target (75 to 80 mmHg) was associated with increased hospital mortality compared with a lower MAP target (60 to 65 mmHg; 60 versus 13 percent) [<a href="#rid89">89</a>]. The same group subsequently reported outcomes in a nonblinded randomized trial of 2600 volume-repleted patients with vasodilatory shock who were older than 65 years and 80 percent of whom had sepsis (the "65 trial") [<a href="#rid90">90</a>]. Patients in whom vasopressors were used to target a MAP 60 to 65 mmHg ("permissive hypotension"; median mean MAP 66.7 mmHg) were compared with patients who received "usual care" (MAP at the discretion of the treating clinician; median MAP 72.6 mmHg). Fluid balance, rates of corticosteroid use (roughly one-third), and urine output were similar among the groups. Although the 90 day mortality was no different, the point estimate favored the permissive hypotension treatment strategy (41 versus 44 percent; adjusted odds ratio 0.82, 95% CI 0.68-0.98) and patients in the permissive hypotension group received lower doses of vasopressors for shorter duration. Importantly, there were no differences in the rates of cognitive dysfunction, cardiac arrhythmias, or acute renal failure. Although the prespecified outcome of superiority was not met, this trial suggests that at minimum, permissive hypotension was not harmful and supports the use of lower than usual target MAPs. It also suggests that similar to observations in other trials, clinicians tend to "overshoot" the target when a target MAP is set. However, several flaws including bias due to lack of blinding and a higher than usual mortality in the usual care group may limit interpretation of this study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two meta-analyses that did <strong>not</strong> include the "65 trial" above [<a href="#rid90">90</a>] reported increased mortality in patients in whom a higher MAP was targeted with vasopressor use for greater than six hours [<a href="#rid91">91</a>] and a greater risk of supraventricular cardiac arrhythmias [<a href="#rid92">92</a>]. Another meta-analysis found no difference in mortality or the need for renal replacement therapy when higher versus lower MAP targets were used [<a href="#rid93">93</a>].</p><p></p><p class="headingAnchor" id="H480587858"><span class="h2">Hemodynamic</span><span class="headingEndMark"> — </span>Static or dynamic predictors of fluid responsiveness should be employed in order to determine further fluid management. Guidelines state a preference for dynamic measures [<a href="#rid3">3</a>] since they are more accurate than static measures (eg, CVP) at predicting fluid responsiveness. However whether the use of dynamic predictors improve clinically impactful outcomes such as mortality remains unproven.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Static</strong> – Traditionally, in addition to MAP, the following static CVC measurements were used to determine adequate fluid management:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CVP at a target of 8 to 12 mmHg</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>ScvO<sub>2</sub> ≥70 percent (≥65 percent if sample is drawn off a PAC)</p><p></p><p class="bulletIndent1">While one early trial of patients with septic shock reported a mortality benefit to these static parameters in a protocol-based therapy, trials published since then (ProCESS, ARISE, ProMISe) have reported no mortality benefit in association with their use [<a href="#rid8">8-11</a>]. (See <a class="local">'Initial resuscitative therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dynamic</strong> – Respiratory changes in the vena caval diameter, radial artery pulse pressure, aortic blood flow peak velocity, left ventricular outflow tract velocity-time integral, and brachial artery blood flow velocity are considered dynamic measures of fluid responsiveness. There is increasing evidence that dynamic measures are more accurate predictors of fluid responsiveness than static measures, as long as the patients are in sinus rhythm and passively ventilated with a sufficient tidal volume. For actively breathing patients or those with irregular cardiac rhythms, an increase in the cardiac output in response to a passive leg-raising maneuver (measured by echocardiography, arterial pulse waveform analysis, or pulmonary artery catheterization) also predicts fluid responsiveness. Choosing among these is dependent upon availability and technical expertise, but a passive leg raising maneuver may be the most accurate and broadly available. Future studies that report improved outcomes (eg, mortality, ventilator free days) in association with their use are needed. Further details are provided separately. (See  <a class="medical medical_review" href="/d/html/107337.html" rel="external">"Novel tools for hemodynamic monitoring in critically ill patients with shock"</a>.)</p><p></p><p class="headingAnchor" id="H370580926"><span class="h2">Laboratory</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lactate clearance</strong> – Although the optimal frequency of measuring serum lactate is unknown, we follow serum lactate (eg, every six hours) in patients with sepsis until the lactate value has clearly fallen. While guidelines promote normalization of lactate [<a href="#rid3">3</a>], lactate-guided resuscitation has not been convincingly associated with improved outcomes.</p><p></p><p class="bulletIndent1">The lactate clearance is defined by the equation [(initial lactate – lactate &gt;2 hours later)/initial lactate] x 100. The lactate clearance and interval change in lactate over the first 12 hours of resuscitation has been evaluated as a potential marker for effective resuscitation [<a href="#rid14">14,94-99</a>]. One meta-analysis of five low quality trials reported that lactate–guided resuscitation resulted in a reduction in mortality compared with resuscitation without lactate [<a href="#rid3">3</a>]. Other meta-analyses reported modest mortality benefit when lactate clearance strategies were used compared with usual care or ScvO<sub>2</sub> normalization [<a href="#rid97">97,98</a>]. However, many of the trials included in these meta-analyses studied heterogeneous populations and used varying definitions of lactate clearance as well as additional variables that potentially affected the outcome.</p><p></p><p class="bulletIndent1">In addition, lactate is a poor marker of tissue perfusion after the restoration of perfusion [<a href="#rid100">100</a>]. As a result, lactate values are generally unhelpful following restoration of perfusion, with one exception: a rising serum lactate level should prompt reevaluation of the adequacy of perfusion. (See  <a class="medical medical_review" href="/d/html/16991.html" rel="external">"Venous blood gases and other alternatives to arterial blood gases"</a>.)</p><p></p><p class="bulletIndent1">Devices that allow measurement of serum lactate levels at the bedside are now available and their use may increase the practicality and utility of serial monitoring of serum lactate levels [<a href="#rid101">101-103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Routine laboratories</strong> – Follow up laboratory studies, in particular platelet count, serum chemistries, and liver function tests are often performed (eg, every six hours) until values have reached normal or baseline. Hyperchloremia should be avoided, but if it is occurs, switching to low chloride-containing (ie, buffered) solutions may be indicated. (See  <a class="medical medical_review" href="/d/html/1607.html" rel="external">"Treatment of severe hypovolemia or hypovolemic shock in adults", section on 'Buffered crystalloid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiology</strong> – Follow up indices of infection are also indicated, including complete blood count and additional cultures. Results should prompt alteration of antibiotic choice if a better and safer regimen can be substituted and/or investigations directed toward source control. (See <a class="local">'Septic focus identification and source control'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Arterial blood gases</strong> – It is prudent to follow worsening or resolution of gas exchange abnormalities, as well as the severity and type of acidosis (eg, resolution of metabolic acidosis and development of hyperchloremic acidosis). Worsening gas exchange may be a clue to the presence of pulmonary edema from excessive fluid resuscitation and also help detect other complications including pneumothorax from central catheter placement, acute respiratory distress syndrome, or venous thromboembolism.</p><p></p><p class="headingAnchor" id="H2630969148"><span class="h1">SEPTIC FOCUS IDENTIFICATION AND SOURCE CONTROL</span><span class="headingEndMark"> — </span>In our experience, a focused history and physical examination is the most valuable method for source detection. Following initial investigations and empiric antimicrobial therapy, further efforts aimed at identifying and controlling the source(s) of infection should be performed in <strong>all</strong> patients with sepsis. In addition, for those who fail despite therapy or those who fail having initially responded to therapy, further investigations aimed at adequacy of the antimicrobial regimen or nosocomial super infection should be considered.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identification</strong> – Additional investigations targeted at the suspected source(s) should be considered in patients with sepsis as promptly as is feasible (eg, within the first 12 hours). This investigation may include imaging (eg, computed tomography, ultrasonography) and sample acquisition (cultures or further diagnostic samples [eg, bronchoalveolar lavage, aspirating fluid collections or joints]); performing additional investigations depends upon the risk, if an intervention is involved, and patient stability. If invasive <em>Candida</em> or <em>Aspergillus</em> infection is suspected, serologic assays for 1,3 beta-D-glucan, galactomannan, and anti-mannan antibodies, if available, may provide early evidence of these fungal infections. These assays are discussed separately. (See  <a class="medical medical_review" href="/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults", section on 'Nonculture methods'</a> and  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Galactomannan antigen detection'</a> and  <a class="medical medical_review" href="/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Beta-D-glucan assay'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Source control</strong> – Source control (ie, physical measures to eradicate a focus of infection and eliminate or treat microbial proliferation and infection) should be undertaken in timely manner when they feasible since undrained foci of infection may not respond to antibiotics alone  (<a class="graphic graphic_table graphicRef58257" href="/d/graphic/58257.html" rel="external">table 3</a>). As examples, potentially infected vascular access devices should be removed (after other vascular access has been established). Other examples include removing other infected implantable devices/hardware, when feasible, abscess drainage (including thoracic empyema and joint), percutaneous nephrostomy, soft tissue debridement or amputation, colectomy (eg, for fulminant <em>Clostridium difficile</em>-associated colitis), and cholecystostomy.</p><p></p><p class="bulletIndent1">The optimal timing of source control is unknown but guidelines suggest no more than 6 to 12 hours after diagnosis since survival is negatively impacted by inadequate source control [<a href="#rid3">3</a>]. Although the general rule of thumb is that source control should occur as soon as possible [<a href="#rid104">104-106</a>], this is not always practical or feasible. In addition, decisions about the type and timing of source control should take into consideration the risk of a specific intervention and its potential risk of complications (eg, death, fistula formation) and the likelihood of success, particularly when there is diagnostic uncertainty regarding the source.</p><p></p><p class="headingAnchor" id="H606622093"><span class="h1">PATIENTS WHO FAIL INITIAL THERAPY</span><span class="headingEndMark"> — </span>Patients having persistent hypoperfusion despite adequate fluid resuscitation and antimicrobial treatment should be reassessed for fluid responsiveness (see <a class="local">'Hemodynamic'</a> above) adequacy of the antimicrobial regimen and septic focus control (see <a class="local">'Septic focus identification and source control'</a> above) as well as the accuracy of the diagnosis of sepsis and/or its source and the possibility that unexpected complications or coexisting problems have occurred (eg, pneumothorax following central venous catheter insertion) (see  <a class="medical medical_review" href="/d/html/98976.html" rel="external">"Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock"</a>). Other options for treatment of persistent hypoperfusion such as the use of vasopressors, glucocorticoids, inotropic therapy, and blood transfusion are discussed in this section.</p><p class="headingAnchor" id="H11"><span class="h2">Vasopressors</span><span class="headingEndMark"> — </span>Intravenous vasopressors are useful in patients who remain hypotensive despite adequate fluid resuscitation or who develop cardiogenic pulmonary edema. Based upon meta-analyses of small randomized trials and observational studies, a paradigm shift in practice has occurred such that most experts prefer to avoid <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> in this population and favor <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> as the first-choice agent  (<a class="graphic graphic_table graphicRef74872" href="/d/graphic/74872.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef99963" href="/d/graphic/99963.html" rel="external">table 5</a>). Although guidelines suggest additional agents including <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> (up to 0.03 units/minute to reduce the dose of norepinephrine) or <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> (for refractory hypotension), practice varies considerably. Guidelines state a preference for central venous and arterial access especially when vasopressor administration is prolonged or high dose, or multiple vasopressors are administered through the same catheter [<a href="#rid3">3</a>]; while this is appropriate, waiting for placement should not delay their administration via a peripheral catheter.</p><p class="bulletIndent1"><span class="glyph">●</span>First agent – Data that support <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> as the first-line single agent in septic shock are derived from numerous trials that compared the use of one vasopressor to another [<a href="#rid107">107-113</a>]. These trials studied norepinephrine versus <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> [<a href="#rid114">114</a>], norepinephrine versus <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> [<a href="#rid115">115-118</a>], norepinephrine versus <a class="drug drug_general" data-topicid="139628" href="/d/drug information/139628.html" rel="external">terlipressin</a> [<a href="#rid119">119-121</a>], norepinephrine versus <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> [<a href="#rid122">122</a>], and vasopressin versus terlipressin [<a href="#rid123">123</a>]. While some of the comparisons found no convincing difference in mortality, length of stay in the intensive care unit or hospital, or incidence of kidney failure [<a href="#rid118">118,124</a>], two meta-analyses reported increased mortality among patients who received <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> during septic shock compared with those who received norepinephrine (53 to 54 versus 48 to 49 percent) [<a href="#rid110">110,125</a>]. Although the causes of death in the two groups were not directly compared, both meta-analyses identified arrhythmic events about twice as often with dopamine than with norepinephrine.</p><p></p><p class="bulletIndent1">However, we believe the initial choice of vasopressor in patients with sepsis is often individualized and determined by additional factors including the presence of coexistent conditions contributing shock (eg, heart failure), arrhythmias, organ ischemia, or agent availability. For example, in patients with significant tachycardia (eg, fast atrial fibrillation, sinus tachycardia &gt;160/minute), agents that completely lack beta adrenergic effects (eg, <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>) may be preferred if it is believed that worsening tachycardia may prompt further decompensation. Similarly, <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a> (DA) may be acceptable in those with significant bradycardia; but low dose DA should <strong>not</strong> be used for the purposes of "renal protection."</p><p></p><p class="bulletIndent1">The impact of agent availability was highlighted by one study of nearly 28,000 patients from 26 hospitals, which reported that during periods of <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> shortages, <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a> was the most frequent alternative agent chosen by intensivists (use rose from 36 to 54 percent) [<a href="#rid126">126</a>]. During the same period, mortality rates from septic shock rose from 36 to 40 percent. Whether this was directly related to phenylephrine use remains unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional agents – The addition of a second or third agent to <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> may be required (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>, or <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with distributive shock from sepsis, <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a> may be added. In a meta-analysis of 23 trials, the addition of vasopressin to catecholamine vasopressors (eg, <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a>, <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a>) resulted in a lower rate of atrial fibrillation (relative risk 0.77, 95% CI 0.67-0.88) [<a href="#rid127">127</a>]. However, when including only studies at low risk of bias, no mortality benefit, reduced requirement for renal replacement therapy, or rate of myocardial injury, stroke, ventricular arrhythmias or length of hospital stay was reported. Although not studied, this effect is likely due to a reduced need for catecholamines which increase the risk of cardiac arrhythmias. This analysis is consistent with other trials and meta-analyses that have demonstrated no mortality benefit from vasopressin and selepressin in patients with septic shock [<a href="#rid128">128-132</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with refractory septic shock associated with a low cardiac output, addition of an inotropic agent may be useful. In a retrospective series of 234 patients with septic shock, among several vasopressor agents added to <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a> (<a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>, <a class="drug drug_general" data-topicid="9384" href="/d/drug information/9384.html" rel="external">dopamine</a>, <a class="drug drug_general" data-topicid="9768" href="/d/drug information/9768.html" rel="external">phenylephrine</a>, <a class="drug drug_general" data-topicid="10039" href="/d/drug information/10039.html" rel="external">vasopressin</a>), inotropic support with dobutamine was associated with a survival advantage (<a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> was not studied) [<a href="#rid133">133</a>]. (See  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Epinephrine'</a> and  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Dobutamine'</a>.)</p><p></p><p>Whether lower vasopressor use is associated with lower mortality is unclear [<a href="#rid134">134</a>].</p><p>Additional information regarding vasopressor use including angiotensin II is provided separately. (See  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Additional therapies</span><span class="headingEndMark"> — </span>Most clinicians agree that additional therapies such as glucocorticoids, inotropic agents, or red blood cell (RBC) transfusion are not routinely warranted in patients with sepsis or septic shock but the use of these therapies maybe useful in refractory cases of septic shock or in special circumstances.</p><p class="headingAnchor" id="H1451354157"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Guidelines recommend against the routine use of glucocorticoids in patients with sepsis. However, corticosteroid therapy may be appropriate in patients with septic shock that is refractory to adequate fluid resuscitation and vasopressor administration. This topic is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1654.html" rel="external">"Glucocorticoid therapy in septic shock in adults"</a>.)</p><p class="headingAnchor" id="H538543258"><span class="h3">Inotropic therapy</span><span class="headingEndMark"> — </span>A trial of inotropic therapy may be warranted in patients who fail to respond to adequate fluids and vasopressors, particularly those who also have diminished cardiac output  (<a class="graphic graphic_table graphicRef99963" href="/d/graphic/99963.html" rel="external">table 5</a>) [<a href="#rid8">8,135-137</a>]. Inotropic therapy should not be used to increase the cardiac index to supranormal levels [<a href="#rid138">138</a>]. <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">Dobutamine</a> is a suitable first-choice agent; <a class="drug drug_general" data-topicid="9409" href="/d/drug information/9409.html" rel="external">epinephrine</a> is a suitable alternative. (See  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Dobutamine'</a>.)</p><p class="headingAnchor" id="H538543274"><span class="h3">Red blood cell transfusions</span><span class="headingEndMark"> — </span>Based upon clinical experience, randomized studies, and guidelines on transfusion of blood products in critically ill patients, we typically reserve red blood cell transfusion for patients with a hemoglobin level ≤7 g/dL. Exceptions include suspicion of concurrent hemorrhagic shock or active myocardial ischemia.</p><p class="bulletIndent1">Support for a restrictive transfusion strategy (goal hemoglobin &gt;7 g/dL) is derived from direct and indirect evidence from randomized studies of patients with septic shock:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One multicenter randomized study of 998 patients with septic shock reported no difference in 28-day mortality between patients who were transfused when the hemoglobin was ≤7 g/dL (restrictive strategy) and patients who were transfused when the hemoglobin was ≤9 g/dL (liberal strategy) [<a href="#rid139">139</a>]. The restrictive strategy resulted in 50 percent fewer red blood cell transfusions (1545 versus 3088 transfusions) and did not have any adverse effect on the rate of ischemic events (7 versus 8 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One randomized trial initially reported a mortality benefit from a protocol that included transfusing patients to a hematocrit goal &gt;30 (hemoglobin level 10 g/dL) [<a href="#rid8">8</a>]. However, similarly designed studies published since then reported no benefit to this strategy [<a href="#rid9">9-11</a>]. These studies are discussed below.</p><p></p><p>In further support of a restrictive approach to transfusion in patients with septic shock is the consensus among experts that transfusing to a goal of &gt;7 g/dL is also preferred in critically ill patients without sepsis [<a href="#rid140">140-142</a>], the details of which are provided separately. (See  <a class="medical medical_review" href="/d/html/1615.html" rel="external">"Use of blood products in the critically ill", section on 'Red blood cells'</a>.)</p><p class="headingAnchor" id="H380596541"><span class="h1">PATIENTS WHO RESPOND TO THERAPY</span><span class="headingEndMark"> — </span>Once patients have demonstrated a response to therapy, attention should be directed towards continuing to control the septic focus, and de-escalation of fluids and antibiotics, as appropriate. This may occur within hours or days, depending upon the indicators of response and the individual patient. (See <a class="local">'Clinical'</a> above and <a class="local">'Hemodynamic'</a> above and <a class="local">'Laboratory'</a> above.)</p><p class="headingAnchor" id="H388230669"><span class="h2">Identification and control of the septic focus</span><span class="headingEndMark"> — </span>Further efforts aimed at identifying and controlling the source of infection should be done if the initial evaluation and investigations fail to identify a source. (See <a class="local">'Septic focus identification and source control'</a> above.)</p><p class="headingAnchor" id="H1948201510"><span class="h2">De-escalation fluids</span><span class="headingEndMark"> — </span>In patients who respond to initial fluid therapy (ie, clinical hemodynamic and laboratory targets are met; usually hours to one to two days), we reduce the rate of or stop fluids, wean vasopressor support, and, if necessary, administer diuretics. While early fluid therapy is appropriate in sepsis, fluids may be unhelpful or harmful when the circulation is no longer fluid responsive. Careful and frequent monitoring is essential because patients with sepsis may develop cardiogenic and noncardiogenic pulmonary edema (ie, acute respiratory distress syndrome [ARDS]).</p><p>Small retrospective studies have reported that fluid overload is common in patients with sepsis and is associated with the increased performance of medical interventions (eg, diuresis, thoracentesis); the effect of fluid overload and such interventions on mortality and functional recovery in sepsis is unclear [<a href="#rid143">143-145</a>]. Data that support fluid restriction in this population include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with ARDS or sepsis, a restrictive approach to intravenous fluid administration has been shown to decrease the duration of mechanical ventilation and ICU stay, compared with a more liberal approach [<a href="#rid146">146-148</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another trial has shown no difference in mortality when fluid restriction was compared with a more liberal approach [<a href="#rid148">148</a>]. In this trial of 1554 patients with sepsis who had received at least 1 liter of fluid and were within 12 hours of the onset of shock, patients were randomized to receive either restricted intravenous fluid (ie, infusion stopped, small boluses given when needed for organ perfusion, low urine output, or insensible losses) or standard intravenous fluid therapy. There was no difference in the 90-day mortality or adverse effects. Cumulatively, at 90 days, patients in the restrictive group received approximately 2 liters less of fluids than patients in the standard group. While these data are encouraging and support safety of a restrictive approach to fluid de-escalation, both groups had received a median of 3 liters of fluid before randomization, the intervention was not blinded, and there were more violations in the restrictive group (22 versus 13 percent). Interestingly, the standard fluids group received less fluid than patients in some of the original sepsis trials [<a href="#rid8">8</a>], suggesting that practice has swung in favor of implementing a fluid-restricted approach to sepsis resuscitation. More studies are needed to guide de-escalation in patients with sepsis. (See  <a class="medical medical_review" href="/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults", section on 'Conservative fluid management'</a>.)</p><p></p><p class="headingAnchor" id="H3322210459"><span class="h2">De-escalation and duration of antibiotics</span><span class="headingEndMark"> — </span>It is appropriate that de-escalation and duration of antimicrobial agents be assessed daily [<a href="#rid149">149,150</a>]. When uncertain, it is also appropriate to obtain an infectious diseases consultation to facilitate good antimicrobial stewardship.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>De-escalation</strong> – After culture and susceptibility results return and/or after patients clinically improve, we recommend that antimicrobial therapy be narrowed (typically a few days). When possible, antimicrobial therapy should also be pathogen and susceptibility directed (also known as targeted/definitive therapy). However, since no pathogen is identified in approximately 50 percent of patients, de-escalation of empiric therapy requires a component of clinical judgement. For example, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> typically is discontinued if no methicillin-resistant <em>Staphylococcus</em> is cultured.</p><p></p><p class="bulletIndent1">While there is no consensus on de-escalation criteria, most experts use follow-up clinical (improved vital signs), laboratory and imaging data, and a fixed course of broad-spectrum therapy (eg, three to five days).</p><p></p><p class="bulletIndent1">There are no high quality trials testing safety of de-escalation of antibiotic therapy in adult patients with sepsis or septic shock [<a href="#rid151">151-155</a>]. However, most observational trials report equivalent or improved outcomes with these fixed strategies of de-escalation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – The duration of antibiotics should be individualized. For most patients, the duration of therapy is typically three to eight days [<a href="#rid156">156-159</a>]. However, longer courses are appropriate in patients who have a slow clinical response, an undrainable focus of infection, bacteremia with <em>S. aureus</em>, some fungal (eg, deep <em>Candida</em> infections) or viral infections (eg, herpes or cytomegalovirus), endocarditis, osteomyelitis, large abscesses, highly resistant gram-negative pathogens with marginal or limited sensitivities, neutropenia, or immunologic deficiencies [<a href="#rid160">160-165</a>]. Similarly, shorter courses may be acceptable in patients with negative cultures and rapid resolution of sepsis and laboratory studies. In patients who are neutropenic, antibiotic treatment should continue until the neutropenia has resolved or the planned antibiotic course is complete, whichever is longer. In nonneutropenic patients in whom infection is thoroughly excluded, antibiotics should be discontinued as early as is feasible to minimize colonization or infection with drug-resistant microorganisms and superinfection with other pathogens. Occasionally, shorter courses may be appropriate (eg, patients with pyelonephritis, urinary sepsis, or peritonitis who have rapid resolution of source control) [<a href="#rid166">166-169</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of </strong><strong>procalcitonin</strong> – Although many institutions and guidelines support the use of procalcitonin to limit antibiotic (empiric or therapeutic) use in critically ill patients with suspected infection or documented infection, the evidence to support this practice is limited. While one randomized open-label trial of critically ill patients with infection reported a mortality benefit when the duration of antibiotic use was guided by normalization of procalcitonin levels [<a href="#rid170">170</a>], several randomized trials and meta-analyses found that using procalcitonin-guided algorithms to guide antimicrobial de-escalation did not result in any mortality benefit [<a href="#rid171">171-177</a>]. However, most trials report a reduction in the duration of antibiotic therapy (on average one day). One retrospective analysis suggested that use of procalcitonin was associated with lower hospital and ICU length of stay, but no clinically meaningful outcomes were measured in this study [<a href="#rid178">178</a>]. Other studies suggest that procalcitonin may distinguish infectious from noninfectious conditions and may therefore facilitate the decision to de-escalate empiric therapy [<a href="#rid171">171,179-181</a>]. However, procalcitonin's greatest utility is in guiding antibiotic discontinuation in patients with known community-acquired pneumonia and acute bronchitis; thus measuring procalcitonin in these populations is appropriate. (See  <a class="medical medical_review" href="/d/html/114753.html" rel="external">"Procalcitonin use in lower respiratory tract infections"</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h1">SUPPORTIVE THERAPIES</span><span class="headingEndMark"> — </span>Details regarding supportive therapies needed for the care of critically ill patients, including those with sepsis are provided separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Blood product infusion (see  <a class="medical medical_review" href="/d/html/1615.html" rel="external">"Use of blood products in the critically ill"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutrition (see  <a class="medical medical_review" href="/d/html/1617.html" rel="external">"Nutrition support in intubated critically ill adult patients: Initial evaluation and prescription"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stress ulcer prophylaxis (see  <a class="medical medical_review" href="/d/html/1611.html" rel="external">"Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neuromuscular blocking agents (see  <a class="medical medical_review" href="/d/html/1590.html" rel="external">"Neuromuscular blocking agents in critically ill patients: Use, agent selection, administration, and adverse effects"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism prophylaxis (see  <a class="medical medical_review" href="/d/html/1346.html" rel="external">"Prevention of venous thromboembolic disease in acutely ill hospitalized medical adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intensive insulin therapy (see  <a class="medical medical_review" href="/d/html/1600.html" rel="external">"Glycemic control in critically ill adult and pediatric patients"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>External cooling or antipyretics (see  <a class="medical medical_review" href="/d/html/1624.html" rel="external">"Fever in the intensive care unit", section on 'Management'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mechanical ventilation, sedation, weaning (see  <a class="medical medical_review" href="/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a> and  <a class="medical medical_review" href="/d/html/1606.html" rel="external">"Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal"</a> and  <a class="medical medical_review" href="/d/html/1650.html" rel="external">"Initial weaning strategy in mechanically ventilated adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Investigational therapies for sepsis and acute respiratory distress syndrome (eg, intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>, antithrombin, thrombomodulin, heparin, cytokine and toxin inactivators, as well as hemofiltration, statins, beta-2 agonists, beta blockade, and <a class="drug drug_general" data-topicid="9776" href="/d/drug information/9776.html" rel="external">vitamin C</a>) (see  <a class="medical medical_review" href="/d/html/1631.html" rel="external">"Investigational and ineffective pharmacologic therapies for sepsis"</a> and  <a class="medical medical_review" href="/d/html/1618.html" rel="external">"Acute respiratory distress syndrome: Investigational or ineffective therapies in adults"</a>)</p><p></p><p class="headingAnchor" id="H1365794740"><span class="h1">PREGNANCY</span><span class="headingEndMark"> — </span>The optimal way to manage sepsis in pregnancy is unknown but most experts use the same principles as outlined in this topic being cognizant of the altered hemodynamics of pregnancy. Guidelines have been proposed but have not been validated [<a href="#rid182">182</a>]. Further details regarding the management of critically ill pregnant patients are provided separately. (See  <a class="medical medical_review" href="/d/html/1629.html" rel="external">"Critical illness during pregnancy and the peripartum period"</a>.)</p><p class="headingAnchor" id="H784619429"><span class="h1">POSTSEPSIS CARE</span><span class="headingEndMark"> — </span>For survivors of sepsis, attention should be paid to follow-up care and the recognition of post-intensive care syndrome (PICS). Further details regarding PICS and prognosis of patients with sepsis are provided separately. (See  <a class="medical medical_review" href="/d/html/88330.html" rel="external">"Post-intensive care syndrome (PICS) in adults: Clinical features and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/d/html/1657.html" rel="external">"Sepsis syndromes in adults: Epidemiology, definitions, clinical presentation, diagnosis, and prognosis", section on 'Prognosis'</a>.)</p><p class="headingAnchor" id="H1321087472"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111943.html" rel="external">"Society guideline links: Sepsis in children and adults"</a>.)</p><p class="headingAnchor" id="H12439456"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16928.html" rel="external">"Patient education: Sepsis in adults (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H31"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – For patients with sepsis and septic shock, therapeutic priorities include securing the airway, correcting hypoxemia, and establishing appropriate vascular access for the early administration of fluids and antibiotics  (<a class="graphic graphic_table graphicRef143200" href="/d/graphic/143200.html" rel="external">table 1</a>). Simultaneously obtaining the following is preferable (within 45 minutes) but should not delay the administration of fluids and antibiotics (see <a class="local">'Immediate evaluation and management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Routine laboratory studies</p><p class="bulletIndent2"><span class="glyph">•</span>Serum lactate</p><p class="bulletIndent2"><span class="glyph">•</span>Arterial blood gases</p><p class="bulletIndent2"><span class="glyph">•</span>Blood cultures (aerobic and anaerobic) from two distinct venipuncture sites and from all indwelling vascular access devices; it is preferable that blood cultures be drawn before the initiation of antibiotics</p><p class="bulletIndent2"><span class="glyph">•</span>Cultures from easily accessible sites (eg, sputum, urine)</p><p class="bulletIndent2"><span class="glyph">•</span>Imaging of suspected sources</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial resuscitation</strong> – For patients with sepsis and septic shock, we suggest the infusion of intravenous fluids (30 mL/kg), commencing within the first hour and completed within the first three hours of presentation, rather than vasopressors, inotropes, or red blood cell transfusions (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Initial resuscitative therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravenous fluids</strong> – Fluid boluses are the preferred method of administration and should be repeated until blood pressure and tissue perfusion are acceptable, pulmonary edema ensues, or there is no further response. (See <a class="local">'Intravenous fluids (first three hours)'</a> above.)</p><p></p><p class="bulletIndent2">Crystalloid solutions (eg, normal <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> or Ringer's lactate) are our preferred resuscitation fluid. Balanced crystalloid may be preferred if there is a perceived need to avoid or treat the hyperchloremia that occurs when large volumes of nonbuffered crystalloid (eg, normal saline) are administered. We recommend that a hyperoncotic starch solution <strong>not</strong> be administered (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Choice of fluid'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotics</strong> – For patients with sepsis, we recommend that optimal doses of empiric broad spectrum intravenous therapy with one or more antimicrobials be administered in a prompt fashion (eg, within one hour) of presentation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). Broad spectrum is defined as therapeutic agent(s) with sufficient activity to cover a broad range of gram-negative and positive organisms, and, if suspected, against fungi and viruses. (See <a class="local">'Empiric antibiotic therapy (first hour)'</a> above and <a class="local">'Initial resuscitative therapy'</a> above.)</p><p></p><p class="bulletIndent2">For patients with septic shock associated with likely gram-negative sepsis, we suggest consideration of the use of two antibiotics from different classes to ensure effective treatment of resistant organisms.</p><p></p><p class="bulletIndent2">Agent selection depends upon patient's history, comorbidities, immune defects, clinical context, suspected site of infection, presence of invasive devices, Gram stain data, and local prevalence and resistance patterns. The routine administration of antifungal therapy is not warranted in nonneutropenic patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – For most patients with sepsis and septic shock, we recommend that fluid management be guided using clinical targets including mean arterial pressure 60 to 70 mmHg (<a class="calc calc_professional" href="/d/html/101851.html" rel="external">calculator 1</a>) and urine output ≥0.5 mL/kg/hour (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Monitor response'</a> above and <a class="local">'Clinical'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodynamics</strong> – In addition, while dynamic measures of fluid responsiveness (eg, respiratory changes in the radial artery pulse pressure) are preferred, static measures of determining adequacy of fluid administration (eg, central venous pressure 8 to 12 mmHg or central venous oxygen saturation ≥70 percent) may be more readily available. (See <a class="local">'Monitoring catheters'</a> above and <a class="local">'Hemodynamic'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Laboratory</strong> – Serum lactate should be followed (eg, every six hours) until there is a definitive clinical response. It is prudent that other measures of the overall response to infection also be followed (eg, routine laboratory studies, arterial blood gases, microbiology studies). (See <a class="local">'Laboratory'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Source control</strong> – Following initial investigations and empiric antimicrobial therapy, further efforts aimed at identifying and controlling the source(s) of infection (ideally within 6 to 12 hours) should be performed in <strong>all</strong> patients with sepsis  (<a class="graphic graphic_table graphicRef58257" href="/d/graphic/58257.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef59769" href="/d/graphic/59769.html" rel="external">table 2</a>). In addition, for those who fail despite therapy or those who fail having initially responded to therapy, further investigations aimed at removal of devices suspected to be infected, adequacy of the antimicrobial regimen, or nosocomial super infection should be considered. (See <a class="local">'Septic focus identification and source control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who fail initial therapy</strong> – For patients with sepsis who remain hypotensive despite adequate fluid resuscitation (eg, 3 L in first three hours), we recommend vasopressors (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>); the preferred initial agent is <a class="drug drug_general" data-topicid="9709" href="/d/drug information/9709.html" rel="external">norepinephrine</a>  (<a class="graphic graphic_table graphicRef99963" href="/d/graphic/99963.html" rel="external">table 5</a>). For patients who are refractory to intravenous fluid and vasopressor therapy, additional therapies, such as glucocorticoids, inotropic therapy, and blood transfusions, can be administered on an individual basis. We typically reserve red blood cell transfusion for patients with a hemoglobin level &lt;7 g/dL. (See <a class="local">'Additional therapies'</a> above and  <a class="medical medical_review" href="/d/html/1619.html" rel="external">"Use of vasopressors and inotropes", section on 'Choice of agent in septic shock'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who respond to therapy</strong> – For patients with sepsis who have demonstrated a response to therapy, we suggest that the rate of fluid administration should be reduced or stopped, vasopressor support weaned, and, if necessary, diuretics administered. We also recommend that antimicrobial therapy be narrowed once pathogen identification and susceptibility data return. Antimicrobial therapy should be pathogen and susceptibility directed for a total duration of 7 to 10 days, although shorter or longer courses are appropriate for select patients. (See <a class="local">'Patients who respond to therapy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Elixhauser A, Friedman B, Stranges E. Septicemia in U.S. Hospitals, 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf (Accessed on February 15, 2013).</li><li><a class="nounderline abstract_t">Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801.</a></li><li><a class="nounderline abstract_t">Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063.</a></li><li><a class="nounderline abstract_t">Howell MD, Davis AM. Management of Sepsis and Septic Shock. JAMA 2017; 317:847.</a></li><li><a class="nounderline abstract_t">IDSA Sepsis Task Force. Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines. Clin Infect Dis 2018; 66:1631.</a></li><li><a class="nounderline abstract_t">Luce JM. Pathogenesis and management of septic shock. Chest 1987; 91:883.</a></li><li><a class="nounderline abstract_t">Ghosh S, Latimer RD, Gray BM, et al. Endotoxin-induced organ injury. Crit Care Med 1993; 21:S19.</a></li><li><a class="nounderline abstract_t">Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.</a></li><li><a class="nounderline abstract_t">ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370:1683.</a></li><li><a class="nounderline abstract_t">ARISE Investigators, ANZICS Clinical Trials Group, Peake SL, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014; 371:1496.</a></li><li><a class="nounderline abstract_t">Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015; 372:1301.</a></li><li><a class="nounderline abstract_t">Angus DC, Barnato AE, Bell D, et al. A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators. Intensive Care Med 2015; 41:1549.</a></li><li><a class="nounderline abstract_t">PRISM Investigators. Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. N Engl J Med 2017.</a></li><li><a class="nounderline abstract_t">Casserly B, Phillips GS, Schorr C, et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med 2015; 43:567.</a></li><li><a class="nounderline abstract_t">Tang Y, Choi J, Kim D, et al. Clinical predictors of adverse outcome in severe sepsis patients with lactate 2-4 mM admitted to the hospital. QJM 2015; 108:279.</a></li><li><a class="nounderline abstract_t">Haas SA, Lange T, Saugel B, et al. Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients. Intensive Care Med 2016; 42:202.</a></li><li><a class="nounderline abstract_t">Cheng MP, Stenstrom R, Paquette K, et al. Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis: A Diagnostic Study. Ann Intern Med 2019; 171:547.</a></li><li><a class="nounderline abstract_t">Pepper DJ, Sun J, Rhee C, et al. Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. Chest 2019; 155:1109.</a></li><li><a class="nounderline abstract_t">Kyriazopoulou E, Liaskou-Antoniou L, Adamis G, et al. Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial. Am J Respir Crit Care Med 2021; 203:202.</a></li><li><a class="nounderline abstract_t">Lu Y, Zhang H, Teng F, et al. Early Goal-Directed Therapy in Severe Sepsis and Septic Shock: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. J Intensive Care Med 2018; 33:296.</a></li><li><a class="nounderline abstract_t">Andrews B, Semler MW, Muchemwa L, et al. Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial. JAMA 2017; 318:1233.</a></li><li><a class="nounderline abstract_t">Lane DJ, Wunsch H, Saskin R, et al. Association Between Early Intravenous Fluids Provided by Paramedics and Subsequent In-Hospital Mortality Among Patients With Sepsis. JAMA Netw Open 2018; 1:e185845.</a></li><li><a class="nounderline abstract_t">Hernández G, Ospina-Tascón GA, Damiani LP, et al. Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial. JAMA 2019; 321:654.</a></li><li><a class="nounderline abstract_t">Zampieri FG, Damiani LP, Bakker J, et al. Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels among Patients with Septic Shock. A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial. Am J Respir Crit Care Med 2020; 201:423.</a></li><li><a class="nounderline abstract_t">Putowski Z, Gołdyn M, Pluta MP, et al. Correlation Between Mean Arterial Pressure and Capillary Refill Time in Patients with Septic Shock: A Systematic Review and Meta-analysis. J Intensive Care Med 2023; 38:838.</a></li><li><a class="nounderline abstract_t">Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N Engl J Med 2017; 376:2235.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Prevention and Early Treatment of Acute Lung Injury Clinical Trials Network, Shapiro NI, Douglas IS, et al. Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension. N Engl J Med 2023; 388:499.</a></li><li><a class="nounderline abstract_t">Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350:2247.</a></li><li><a class="nounderline abstract_t">Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 2014; 370:1412.</a></li><li><a class="nounderline abstract_t">Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124.</a></li><li><a class="nounderline abstract_t">Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125.</a></li><li><a class="nounderline abstract_t">Rochwerg B, Alhazzani W, Sindi A, et al. Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med 2014; 161:347.</a></li><li><a class="nounderline abstract_t">Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ 2014; 349:g4561.</a></li><li><a class="nounderline abstract_t">Rochwerg B, Alhazzani W, Gibson A, et al. Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis. Intensive Care Med 2015; 41:1561.</a></li><li><a class="nounderline abstract_t">Raghunathan K, Bonavia A, Nathanson BH, et al. Association between Initial Fluid Choice and Subsequent In-hospital Mortality during the Resuscitation of Adults with Septic Shock. Anesthesiology 2015; 123:1385.</a></li><li><a class="nounderline abstract_t">Xu JY, Chen QH, Xie JF, et al. Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials. Crit Care 2014; 18:702.</a></li><li><a class="nounderline abstract_t">Jiang L, Jiang S, Zhang M, et al. Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis. PLoS One 2014; 9:e114666.</a></li><li><a class="nounderline abstract_t">Asfar P, Schortgen F, Boisramé-Helms J, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respir Med 2017; 5:180.</a></li><li><a class="nounderline abstract_t">Peltan ID, Mitchell KH, Rudd KE, et al. Physician Variation in Time to Antimicrobial Treatment for Septic Patients Presenting to the Emergency Department. Crit Care Med 2017; 45:1011.</a></li><li><a class="nounderline abstract_t">Amaral AC, Fowler RA, Pinto R, et al. Patient and Organizational Factors Associated With Delays in Antimicrobial Therapy for Septic Shock. Crit Care Med 2016; 44:2145.</a></li><li><a class="nounderline abstract_t">Filbin MR, Thorsen JE, Zachary TM, et al. Antibiotic Delays and Feasibility of a 1-Hour-From-Triage Antibiotic Requirement: Analysis of an Emergency Department Sepsis Quality Improvement Database. Ann Emerg Med 2020; 75:93.</a></li><li><a class="nounderline abstract_t">Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38:1045.</a></li><li><a class="nounderline abstract_t">Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742.</a></li><li><a class="nounderline abstract_t">Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146.</a></li><li><a class="nounderline abstract_t">Harbarth S, Garbino J, Pugin J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529.</a></li><li><a class="nounderline abstract_t">Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127.</a></li><li><a class="nounderline abstract_t">Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589.</a></li><li><a class="nounderline abstract_t">Schramm GE, Johnson JA, Doherty JA, et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069.</a></li><li><a class="nounderline abstract_t">Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237.</a></li><li><a class="nounderline abstract_t">Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014; 42:1749.</a></li><li><a class="nounderline abstract_t">Whiles BB, Deis AS, Simpson SQ. Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients. Crit Care Med 2017; 45:623.</a></li><li><a class="nounderline abstract_t">Liu VX, Fielding-Singh V, Greene JD, et al. The Timing of Early Antibiotics and Hospital Mortality in Sepsis. Am J Respir Crit Care Med 2017; 196:856.</a></li><li><a class="nounderline abstract_t">Johnson MT, Reichley R, Hoppe-Bauer J, et al. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011; 39:1859.</a></li><li><a class="nounderline abstract_t">Verhoef J, Hustinx WM, Frasa H, Hoepelman AI. Issues in the adjunct therapy of severe sepsis. J Antimicrob Chemother 1996; 38:167.</a></li><li><a class="nounderline abstract_t">Sibbald WJ, Vincent JL. Round table conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23:394.</a></li><li><a class="nounderline abstract_t">Septimus EJ, Coopersmith CM, Whittle J, et al. Sepsis National Hospital Inpatient Quality Measure (SEP-1): Multistakeholder Work Group Recommendations for Appropriate Antibiotics for the Treatment of Sepsis. Clin Infect Dis 2017; 65:1565.</a></li><li><a class="nounderline abstract_t">De Waele JJ, Akova M, Antonelli M, et al. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance. Intensive Care Med 2018; 44:189.</a></li><li><a class="nounderline abstract_t">Savage RD, Fowler RA, Rishu AH, et al. Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study. CMAJ Open 2016; 4:E569.</a></li><li><a class="nounderline abstract_t">Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445.</a></li><li><a class="nounderline abstract_t">Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352:1436.</a></li><li><a class="nounderline abstract_t">Qian ET, Casey JD, Wright A, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA 2023; 330:1557.</a></li><li><a class="nounderline abstract_t">Rubinstein E, Lode H, Grassi C. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group. Clin Infect Dis 1995; 20:1217.</a></li><li><a class="nounderline abstract_t">Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother 1996; 40:1108.</a></li><li><a class="nounderline abstract_t">Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.</a></li><li><a class="nounderline abstract_t">Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.</a></li><li><a class="nounderline abstract_t">Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014; :CD003344.</a></li><li><a class="nounderline abstract_t">Cortegiani A, Russotto V, Maggiore A, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2016; :CD004920.</a></li><li><a class="nounderline abstract_t">Bailly S, Bouadma L, Azoulay E, et al. Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients. Am J Respir Crit Care Med 2015; 191:1139.</a></li><li><a class="nounderline abstract_t">Timsit JF, Azoulay E, Schwebel C, et al. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial. JAMA 2016; 316:1555.</a></li><li><a class="nounderline abstract_t">Pletz MW, Bloos F, Burkhardt O, et al. Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock. Intensive Care Med 2010; 36:979.</a></li><li><a class="nounderline abstract_t">van Zanten AR, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23:422.</a></li><li><a class="nounderline abstract_t">Blot S, Koulenti D, Akova M, et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study. Crit Care 2014; 18:R99.</a></li><li><a class="nounderline abstract_t">Zelenitsky S, Rubinstein E, Ariano R, et al. Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock. Int J Antimicrob Agents 2013; 41:255.</a></li><li><a class="nounderline abstract_t">Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279:125.</a></li><li><a class="nounderline abstract_t">Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623.</a></li><li><a class="nounderline abstract_t">Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials. Am J Respir Crit Care Med 2016; 194:681.</a></li><li><a class="nounderline abstract_t">Zhao HY, Gu J, Lyu J, et al. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study. Chin Med J (Engl) 2017; 130:1139.</a></li><li><a class="nounderline abstract_t">Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64:142.</a></li><li><a class="nounderline abstract_t">Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 2016; 42:1535.</a></li><li><a class="nounderline abstract_t">Monti G, Bradic N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA 2023; 330:141.</a></li><li><a class="nounderline abstract_t">Guidet B, Leblanc G, Simon T, et al. Effect of Systematic Intensive Care Unit Triage on Long-term Mortality Among Critically Ill Elderly Patients in France: A Randomized Clinical Trial. JAMA 2017; 318:1450.</a></li><li><a class="nounderline abstract_t">Valley TS, Sjoding MW, Ryan AM, et al. Association of Intensive Care Unit Admission With Mortality Among Older Patients With Pneumonia. JAMA 2015; 314:1272.</a></li><li><a class="nounderline abstract_t">Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366:472.</a></li><li><a class="nounderline abstract_t">Richard C, Warszawski J, Anguel N, et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2003; 290:2713.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354:2213.</a></li><li><a class="nounderline abstract_t">Michard F, Boussat S, Chemla D, et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med 2000; 162:134.</a></li><li><a class="nounderline abstract_t">Walley KR. Use of central venous oxygen saturation to guide therapy. Am J Respir Crit Care Med 2011; 184:514.</a></li><li><a class="nounderline abstract_t">Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014; 370:1583.</a></li><li><a class="nounderline abstract_t">Lamontagne F, Meade MO, Hébert PC, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 2016; 42:542.</a></li><li><a class="nounderline abstract_t">Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial. JAMA 2020; 323:938.</a></li><li><a class="nounderline abstract_t">Lamontagne F, Day AG, Meade MO, et al. Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock. Intensive Care Med 2018; 44:12.</a></li><li><a class="nounderline abstract_t">Hylands M, Moller MH, Asfar P, et al. A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension. Can J Anaesth 2017; 64:703.</a></li><li><a class="nounderline abstract_t">Carayannopoulos KL, Pidutti A, Upadhyaya Y, et al. Mean Arterial Pressure Targets and Patient-Important Outcomes in Critically Ill Adults: A Systematic Review and Meta-Analysis of Randomized Trials. Crit Care Med 2023; 51:241.</a></li><li><a class="nounderline abstract_t">Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010; 303:739.</a></li><li><a class="nounderline abstract_t">Liu V, Morehouse JW, Soule J, et al. Fluid volume, lactate values, and mortality in sepsis patients with intermediate lactate values. Ann Am Thorac Soc 2013; 10:466.</a></li><li><a class="nounderline abstract_t">Jansen TC, van Bommel J, Schoonderbeek FJ, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 2010; 182:752.</a></li><li><a class="nounderline abstract_t">Gu WJ, Zhang Z, Bakker J. Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. Intensive Care Med 2015; 41:1862.</a></li><li><a class="nounderline abstract_t">Simpson SQ, Gaines M, Hussein Y, Badgett RG. Early goal-directed therapy for severe sepsis and septic shock: A living systematic review. J Crit Care 2016; 36:43.</a></li><li><a class="nounderline abstract_t">McCallister R, Nuppnau M, Sjoding MW, et al. In Patients With Sepsis, Initial Lactate Clearance Is Confounded Highly by Comorbidities and Poorly Predicts Subsequent Lactate Trajectory. Chest 2023; 164:667.</a></li><li><a class="nounderline abstract_t">Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000; 117:260.</a></li><li><a class="nounderline abstract_t">Karon BS, Scott R, Burritt MF, Santrach PJ. Comparison of lactate values between point-of-care and central laboratory analyzers. Am J Clin Pathol 2007; 128:168.</a></li><li><a class="nounderline abstract_t">Ismail F, Mackay WG, Kerry A, et al. The accuracy and timeliness of a Point Of Care lactate measurement in patients with Sepsis. Scand J Trauma Resusc Emerg Med 2015; 23:68.</a></li><li><a class="nounderline abstract_t">Singer AJ, Taylor M, LeBlanc D, et al. ED bedside point-of-care lactate in patients with suspected sepsis is associated with reduced time to iv fluids and mortality. Am J Emerg Med 2014; 32:1120.</a></li><li><a class="nounderline abstract_t">Azuhata T, Kinoshita K, Kawano D, et al. Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock. Crit Care 2014; 18:R87.</a></li><li><a class="nounderline abstract_t">Buck DL, Vester-Andersen M, Møller MH, Danish Clinical Register of Emergency Surgery. Surgical delay is a critical determinant of survival in perforated peptic ulcer. Br J Surg 2013; 100:1045.</a></li><li><a class="nounderline abstract_t">Karvellas CJ, Abraldes JG, Zepeda-Gomez S, et al. The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitis-associated septic shock. Aliment Pharmacol Ther 2016; 44:755.</a></li><li><a class="nounderline abstract_t">Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103:1826.</a></li><li><a class="nounderline abstract_t">De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779.</a></li><li><a class="nounderline abstract_t">Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272:1354.</a></li><li><a class="nounderline abstract_t">De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*. Crit Care Med 2012; 40:725.</a></li><li><a class="nounderline abstract_t">Patel GP, Grahe JS, Sperry M, et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010; 33:375.</a></li><li><a class="nounderline abstract_t">Mathur SM, Dhunna R, Chakraborty A. Comparison of dopamine and norepinephrine in the management of septic shock using impedance cardiography. Ind J Crit Care Med 2007; 11:186.</a></li><li><a class="nounderline abstract_t">Ruokonen E, Takala J, Kari A, et al. Regional blood flow and oxygen transport in septic shock. Crit Care Med 1993; 21:1296.</a></li><li><a class="nounderline abstract_t">Morelli A, Ertmer C, Rehberg S, et al. Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial. Crit Care 2008; 12:R143.</a></li><li><a class="nounderline abstract_t">Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009; 37:811.</a></li><li><a class="nounderline abstract_t">Lauzier F, Lévy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006; 32:1782.</a></li><li><a class="nounderline abstract_t">Luckner G, Dünser MW, Stadlbauer KH, et al. Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome. Crit Care 2006; 10:R40.</a></li><li><a class="nounderline abstract_t">Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. JAMA 2016; 316:509.</a></li><li><a class="nounderline abstract_t">Albanèse J, Leone M, Delmas A, Martin C. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. Crit Care Med 2005; 33:1897.</a></li><li><a class="nounderline abstract_t">Boccara G, Ouattara A, Godet G, et al. Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors. Anesthesiology 2003; 98:1338.</a></li><li><a class="nounderline abstract_t">Liu ZM, Chen J, Kou Q, et al. Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial. Intensive Care Med 2018; 44:1816.</a></li><li><a class="nounderline abstract_t">Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008; 34:2226.</a></li><li><a class="nounderline abstract_t">Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care 2009; 13:R130.</a></li><li><a class="nounderline abstract_t">Havel C, Arrich J, Losert H, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2011; :CD003709.</a></li><li><a class="nounderline abstract_t">Vasu TS, Cavallazzi R, Hirani A, et al. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med 2012; 27:172.</a></li><li><a class="nounderline abstract_t">Vail E, Gershengorn HB, Hua M, et al. Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock. JAMA 2017; 317:1433.</a></li><li><a class="nounderline abstract_t">McIntyre WF, Um KJ, Alhazzani W, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. JAMA 2018; 319:1889.</a></li><li><a class="nounderline abstract_t">Nagendran M, Maruthappu M, Gordon AC, Gurusamy KS. Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-analysis. J Intensive Care Soc 2016; 17:136.</a></li><li><a class="nounderline abstract_t">Gamper G, Havel C, Arrich J, et al. Vasopressors for hypotensive shock. Cochrane Database Syst Rev 2016; 2:CD003709.</a></li><li><a class="nounderline abstract_t">Nagendran M, Russell JA, Walley KR, et al. Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. Intensive Care Med 2019; 45:844.</a></li><li><a class="nounderline abstract_t">Laterre PF, Berry SM, Blemings A, et al. Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial. JAMA 2019; 322:1476.</a></li><li><a class="nounderline abstract_t">Honarmand K, Um KJ, Belley-Côté EP, et al. Canadian Critical Care Society clinical practice guideline: The use of vasopressin and vasopressin analogues in critically ill adults with distributive shock. Can J Anaesth 2020; 67:369.</a></li><li><a class="nounderline abstract_t">Nguyen HB, Lu S, Possagnoli I, Stokes P. Comparative Effectiveness of Second Vasoactive Agents in Septic Shock Refractory to Norepinephrine. J Intensive Care Med 2017; 32:451.</a></li><li><a class="nounderline abstract_t">Richards-Belle A, Hylands M, Muttalib F, et al. Lower Versus Higher Exposure to Vasopressor Therapy in Vasodilatory Hypotension: A Systematic Review With Meta-Analysis. Crit Care Med 2023; 51:254.</a></li><li><a class="nounderline abstract_t">Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32:1928.</a></li><li><a class="nounderline abstract_t">Rhodes A, Bennett ED. Early goal-directed therapy: an evidence-based review. Crit Care Med 2004; 32:S448.</a></li><li><a class="nounderline abstract_t">Bersten AD, Hersch M, Cheung H, et al. The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surgery 1992; 112:549.</a></li><li><a class="nounderline abstract_t">Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296.</a></li><li><a class="nounderline abstract_t">Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014; 371:1381.</a></li><li><a class="nounderline abstract_t">Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340:409.</a></li><li><a class="nounderline abstract_t">Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 2012; 157:49.</a></li><li><a class="nounderline abstract_t">Retter A, Wyncoll D, Pearse R, et al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol 2013; 160:445.</a></li><li><a class="nounderline abstract_t">Kelm DJ, Perrin JT, Cartin-Ceba R, et al. Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death. Shock 2015; 43:68.</a></li><li><a class="nounderline abstract_t">Malbrain ML, Marik PE, Witters I, et al. Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice. Anaesthesiol Intensive Ther 2014; 46:361.</a></li><li><a class="nounderline abstract_t">Mitchell KH, Carlbom D, Caldwell E, et al. Volume Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock. Ann Am Thorac Soc 2015; 12:1837.</a></li><li><a class="nounderline abstract_t">National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wiedemann HP, Wheeler AP, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564.</a></li><li><a class="nounderline abstract_t">Silversides JA, Major E, Ferguson AJ, et al. Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis. Intensive Care Med 2017; 43:155.</a></li><li><a class="nounderline abstract_t">Meyhoff TS, Hjortrup PB, Wetterslev J, et al. Restriction of Intravenous Fluid in ICU Patients with Septic Shock. N Engl J Med 2022; 386:2459.</a></li><li><a class="nounderline abstract_t">Weiss CH, Moazed F, McEvoy CA, et al. Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study. Am J Respir Crit Care Med 2011; 184:680.</a></li><li><a class="nounderline abstract_t">Tabah A, Bassetti M, Kollef MH, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med 2020; 46:245.</a></li><li><a class="nounderline abstract_t">Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 2013; :CD007934.</a></li><li><a class="nounderline abstract_t">Morel J, Casoetto J, Jospé R, et al. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit Care 2010; 14:R225.</a></li><li><a class="nounderline abstract_t">Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014; 40:1399.</a></li><li><a class="nounderline abstract_t">Garnacho-Montero J, Gutiérrez-Pizarraya A, Escoresca-Ortega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med 2014; 40:32.</a></li><li><a class="nounderline abstract_t">Moehring RW, Yarrington ME, Warren BG, et al. Evaluation of an Opt-Out Protocol for Antibiotic De-Escalation in Patients With Suspected Sepsis: A Multicenter, Randomized, Controlled Trial. Clin Infect Dis 2023; 76:433.</a></li><li><a class="nounderline abstract_t">Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</a></li><li><a class="nounderline abstract_t">Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588.</a></li><li><a class="nounderline abstract_t">Choudhury G, Mandal P, Singanayagam A, et al. Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis. Clin Microbiol Infect 2011; 17:1852.</a></li><li><a class="nounderline abstract_t">Pugh R, Grant C, Cooke RP, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; :CD007577.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011; 52:e56.</a></li><li><a class="nounderline abstract_t">Jack L, Bal AM, Harte S, Collier A. International guidelines: the need to standardize the management of candidaemia. Infect Dis (Lond) 2016; 48:779.</a></li><li><a class="nounderline abstract_t">Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.</a></li><li><a class="nounderline abstract_t">Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</a></li><li><a class="nounderline abstract_t">Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med 2015; 372:1996.</a></li><li><a class="nounderline abstract_t">Eliakim-Raz N, Yahav D, Paul M, Leibovici L. Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2013; 68:2183.</a></li><li><a class="nounderline abstract_t">Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669.</a></li><li><a class="nounderline abstract_t">Rattan R, Allen CJ, Sawyer RG, et al. Patients with Complicated Intra-Abdominal Infection Presenting with Sepsis Do Not Require Longer Duration of Antimicrobial Therapy. J Am Coll Surg 2016; 222:440.</a></li><li><a class="nounderline abstract_t">de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 2016; 16:819.</a></li><li><a class="nounderline abstract_t">Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 2011; 171:1322.</a></li><li><a class="nounderline abstract_t">Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 2014; 190:1102.</a></li><li><a class="nounderline abstract_t">Matthaiou DK, Ntani G, Kontogiorgi M, et al. An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients. Intensive Care Med 2012; 38:940.</a></li><li><a class="nounderline abstract_t">Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis. Crit Care 2013; 17:R291.</a></li><li><a class="nounderline abstract_t">Paul M, Dickstein Y, Raz-Pasteur A. Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis. Clin Microbiol Infect 2016; 22:960.</a></li><li><a class="nounderline abstract_t">Andriolo BN, Andriolo RB, Salomão R, Atallah ÁN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev 2017; 1:CD010959.</a></li><li><a class="nounderline abstract_t">Arulkumaran N, Khpal M, Tam K, et al. Effect of Antibiotic Discontinuation Strategies on Mortality and Infectious Complications in Critically Ill Septic Patients: A Meta-Analysis and Trial Sequential Analysis. Crit Care Med 2020; 48:757.</a></li><li><a class="nounderline abstract_t">Balk RA, Kadri SS, Cao Z, et al. Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States. Chest 2017; 151:23.</a></li><li><a class="nounderline abstract_t">Westwood M, Ramaekers B, Whiting P, et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 2015; 19:v.</a></li><li><a class="nounderline abstract_t">Soni NJ, Samson DJ, Galaydick JL, et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 2013; 8:530.</a></li><li><a class="nounderline abstract_t">Schuetz P, Kutz A, Grolimund E, et al. Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial. Int J Cardiol 2014; 175:464.</a></li><li><a class="nounderline abstract_t">Bowyer L, Robinson HL, Barrett H, et al. SOMANZ guidelines for the investigation and management sepsis in pregnancy. Aust N Z J Obstet Gynaecol 2017; 57:540.</a></li></ol></div><div id="topicVersionRevision">Topic 1613 Version 148.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Elixhauser A, Friedman B, Stranges E. Septicemia in U.S. Hospitals, 2009. Agency for Healthcare Research and Quality, Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf (Accessed on February 15, 2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903338" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605781" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28114603" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of Sepsis and Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29182749" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3556056" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pathogenesis and management of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8428492" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Endotoxin-induced organ injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11794169" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Early goal-directed therapy in the treatment of severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635773" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized trial of protocol-based care for early septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25272316" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Goal-directed resuscitation for patients with early septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25776532" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Trial of early, goal-directed resuscitation for septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25952825" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A systematic review and meta-analysis of early goal-directed therapy for septic shock: the ARISE, ProCESS and ProMISe Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28320242" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25479113" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193540" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical predictors of adverse outcome in severe sepsis patients with lactate 2-4 mM admitted to the hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26556617" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe hyperlactatemia, lactate clearance and mortality in unselected critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31525774" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Blood Culture Results Before and After Antimicrobial Administration in Patients With Severe Manifestations of Sepsis: A Diagnostic Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30772386" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32757963" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27756870" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early Goal-Directed Therapy in Severe Sepsis and Septic Shock: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973227" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646296" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association Between Early Intravenous Fluids Provided by Paramedics and Subsequent In-Hospital Mortality Among Patients With Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30772908" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31574228" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels among Patients with Septic Shock. A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37042043" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Correlation Between Mean Arterial Pressure and Capillary Refill Time in Patients with Septic Shock: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28528569" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Time to Treatment and Mortality during Mandated Emergency Care for Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36688507" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Early Restrictive or Liberal Fluid Management for Sepsis-Induced Hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163774" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparison of albumin and saline for fluid resuscitation in the intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635772" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Albumin replacement in patients with severe sepsis or septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22738085" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184958" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intensive insulin therapy and pentastarch resuscitation in severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25047428" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fluid resuscitation in sepsis: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099709" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25904181" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fluid type and the use of renal replacement therapy in sepsis: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414499" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association between Initial Fluid Choice and Subsequent In-hospital Mortality during the Resuscitation of Adults with Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25499187" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Comparison of the effects of albumin and crystalloid on mortality in adult patients with severe sepsis and septic shock: a meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25474401" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Albumin versus other fluids for fluid resuscitation in patients with sepsis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28219612" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28426466" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Physician Variation in Time to Antimicrobial Treatment for Septic Patients Presenting to the Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27441899" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Patient and Organizational Factors Associated With Delays in Antimicrobial Therapy for Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31561998" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antibiotic Delays and Feasibility of a 1-Hour-From-Triage Antibiotic Requirement: Analysis of an Emergency Department Sepsis Quality Improvement Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20048677" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668610" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893372" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14599631" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145881" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625125" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16763516" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19696123" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24717459" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28169944" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increased Time to Initial Antimicrobial Administration Is Associated With Progression to Septic Shock in Severe Sepsis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28345952" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The Timing of Early Antibiotics and Hospital Mortality in Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21499086" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8877531" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Issues in the adjunct therapy of severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7867364" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Round table conference on clinical trials for the treatment of sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29048513" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sepsis National Hospital Inpatient Quality Measure (SEP-1): Multistakeholder Work Group Recommendations for Appropriate Antibiotics for the Treatment of Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29288367" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28018869" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Pathogens and antimicrobial susceptibility profiles in critically ill patients with bloodstream infections: a descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814880" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15814879" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Methicillin-resistant Staphylococcus aureus disease in three communities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37837651" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620002" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired gram-negative infections. Antibiotic Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8723449" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288826" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996699" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24395715" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26772902" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25780856" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27706483" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20336279" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Pharmacokinetics of moxifloxacin in patients with severe sepsis or septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725050" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24887569" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23312606" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440662" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10049277" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974879" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Continuous versus Intermittentβ-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28485312" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398460" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26754759" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37326473" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973065" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effect of Systematic Intensive Care Unit Triage on Long-term Mortality Among Critically Ill Elderly Patients in France: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26393850" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Association of Intensive Care Unit Admission With Mortality Among Older Patients With Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084255" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645314" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714768" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903232" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177882" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Use of central venous oxygen saturation to guide therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635770" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : High versus low blood-pressure target in patients with septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26891677" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32049269" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Effect of Reduced Exposure to Vasopressors on 90-Day Mortality in Older Critically Ill Patients With Vasodilatory Hypotension: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260272" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28497426" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A systematic review of vasopressor blood pressure targets in critically ill adults with hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36661452" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Mean Arterial Pressure Targets and Patient-Important Outcomes in Critically Ill Adults: A Systematic Review and Meta-Analysis of Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179283" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24004068" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Fluid volume, lactate values, and mortality in sepsis patients with intermediate lactate values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20463176" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26154408" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27546746" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Early goal-directed therapy for severe sepsis and septic shock: A living systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37087051" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : In Patients With Sepsis, Initial Lactate Clearance Is Confounded Highly by Comorbidities and Poorly Predicts Subsequent Lactate Trajectory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631227" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Sodium bicarbonate for the treatment of lactic acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17580286" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparison of lactate values between point-of-care and central laboratory analyzers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26383239" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : The accuracy and timeliness of a Point Of Care lactate measurement in patients with Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25082597" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : ED bedside point-of-care lactate in patients with suspected sepsis is associated with reduced time to iv fluids and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24886954" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Time from admission to initiation of surgery for source control is a critical determinant of survival in patients with gastrointestinal perforation with associated septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23754645" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Surgical delay is a critical determinant of survival in perforated peptic ulcer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27506331" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The impact of delayed biliary decompression and anti-microbial therapy in 260 patients with cholangitis-associated septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8404107" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20200382" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Comparison of dopamine and norepinephrine in the treatment of shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7933396" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22036860" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19851126" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Efficacy and safety of dopamine versus norepinephrine in the management of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Comparison of dopamine and norepinephrine in the management of septic shock using impedance cardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8370292" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Regional blood flow and oxygen transport in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017409" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Phenylephrine versus norepinephrine for initial hemodynamic support of patients with septic shock: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237882" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17019548" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542484" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27483065" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148457" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12766641" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Terlipressin versus norepinephrine to correct refractory arterial hypotension after general anesthesia in patients chronically treated with renin-angiotensin system inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29971593" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18654759" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A comparison of epinephrine and norepinephrine in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19664253" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563137" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Vasopressors for hypotensive shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21436167" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28322415" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29801010" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28979478" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Comparative safety and efficacy of vasopressors for mortality in septic shock: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26878401" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Vasopressors for hypotensive shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062052" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577035" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31797234" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Canadian Critical Care Society clinical practice guideline: The use of vasopressin and vasopressin analogues in critically ill adults with distributive shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27189952" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Comparative Effectiveness of Second Vasoactive Agents in Septic Shock Refractory to Norepinephrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36398968" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Lower Versus Higher Exposure to Vasopressor Therapy in Vasodilatory Hypotension: A Systematic Review With Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15343024" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542954" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Early goal-directed therapy: an evidence-based review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1519172" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158437" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25270275" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Lower versus higher hemoglobin threshold for transfusion in septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9971864" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22751760" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Red blood cell transfusion: a clinical practice guideline from the AABB*.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23278459" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247784" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Fluid overload in patients with severe sepsis and septic shock treated with early goal-directed therapy is associated with increased acute need for fluid-related medical interventions and hospital death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432556" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Fluid overload, de-resuscitation, and outcomes in critically ill or injured patients: a systematic review with suggestions for clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26394090" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Volume Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714767" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Comparison of two fluid-management strategies in acute lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27734109" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Conservative fluid management or deresuscitation for patients with sepsis or acute respiratory distress syndrome following the resuscitation phase of critical illness: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35709019" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Restriction of Intravenous Fluid in ICU Patients with Septic Shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21616996" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Prompting physicians to address a daily checklist and process of care and clinical outcomes: a single-site study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31781835" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543557" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21167047" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25091790" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24026297" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36167851" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Evaluation of an Opt-Out Protocol for Antibiotic De-Escalation in Patients With Suspected Sepsis: A Multicenter, Randomized, Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14625336" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21919994" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Seven-day antibiotic courses have similar efficacy to prolonged courses in severe community-acquired pneumonia--a propensity-adjusted analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26301604" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258094" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27415963" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : International guidelines: the need to standardize the management of candidaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26320109" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25992746" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Trial of short-course antimicrobial therapy for intraabdominal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23696620" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302637" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26920994" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Patients with Complicated Intra-Abdominal Infection Presenting with Sepsis Do Not Require Longer Duration of Antimicrobial Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26947523" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21824946" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25295709" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22538461" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : An ESICM systematic review and meta-analysis of procalcitonin-guided antibiotic therapy algorithms in adult critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24330744" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27283148" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Antibiotic de-escalation for bloodstream infections and pneumonia: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28099689" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191414" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Effect of Antibiotic Discontinuation Strategies on Mortality and Infectious Complications in Critically Ill Septic Patients: A Meta-Analysis and Trial Sequential Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27568580" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569153" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23955852" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25005339" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Excluding infection through procalcitonin testing improves outcomes of congestive heart failure patients presenting with acute respiratory symptoms: results from the randomized ProHOSP trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28670748" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : SOMANZ guidelines for the investigation and management sepsis in pregnancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
